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ABSTRACT
Colorectal Cancer (CRC) is the third-most common malignancy for men or women,
with chronic inflammation considered as a primary risk factor. Obesity is also considered
a chronic inflammatory disease and is associated with increased CRC incidence. Further,
obesity and CRC occur in men and women differently with the highest incidence of either
disease found in men, suggesting that female sex hormones may play a protective role in
inflammatory diseases. Macrophages can promote inflammation and are a driving force in
obesity-associated metabolic dysfunction. Conversely, macrophages also contribute to
pro-tumoral responses including, proliferation, angiogenesis and tissue remodeling. This
heterogeneity of macrophage behavior and function within these diseases encourages the
need for macrophage targeted studies.

Currently, the specific role of macrophages

throughout the initiation and progression of these diseases remains unclear. Utilizing
clodronate liposomes to target macrophages, we have uncovered that during late stage
CRC, macrophage depletion is effective at reducing tumor-promoting macrophage
signaling that contributed to reduced tumor burden and a more beneficial microbial
composition. However, clodronate mediated macrophage depletion was ineffective at
rescuing obesity induced insulin resistance due to compensatory neutrophil associated
inflammation. In addition, we examined macrophage behavior within obesity driven CRC.
Using a subcutaneous tumor model following diet induced obesity, we found that both
insulin resistance and tumor growth presented differently in males, females and
ovariectomized (OVX) females. Interestingly, the most severe obesity enhanced tumor
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growth was found in the obese OVX mice. This was consistent with increased M2-like
tumor associated macrophages, increased subcutaneous adiposity and enhanced
macrophage associated adipose tissue inflammation compared to obese females. These
results suggest a protective role of female sex hormones in obesity enhanced CRC which
is potentially mediated by macrophage associated inflammation. Taken together, our
findings confirm a unique role of macrophages and macrophage associated inflammation
in CRC, obesity and obesity-enhanced CRC. These findings are significant in further
elucidating macrophage behavior through the progression of inflammatory driven diseases
and contribute to the mechanistic understanding of sex disparities in obesity associated
CRC.
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CHAPTER 1
INTRODUCTION
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Macrophages are major players in the inflammatory response and are not only the
most abundant immune population in a tumor microenvironment, but also are a driving
force in obesity-associated inflammation leading to metabolic dysfunction. Macrophages
are considered highly plastic immune cells and can assume a variety of functions according
to their environment. They can be generally categorized into two broad but distinct subsets
as either, classically activated (M1), which are pro-inflammatory/anti-cancer or
alternatively activated (M2), which are anti-inflammatory/pro-cancer. However, recent
evidence suggests macrophages exist on a spectrum of diverse phenotypic states rather than
the rigid dichotomy of M1/M2 phenotypes[1]. Such heterogeneity of macrophage behavior
provides uncertainty regarding the role of macrophages in the progression of certain
chronic inflammatory diseases. This led us to explore the role of macrophages and
macrophage associated inflammation in chronic inflammatory diseases: obesity, colorectal
cancer (CRC) and obesity enhanced-CRC.

1.1 Macrophages in Chronic Inflammation
Chronic inflammation is a prolonged condition in which tissue injury and repair
simultaneously occur, leading to tissue remodeling and dysfunction. Chronic inflammation
often begins as a low-grade, smoldering response which lacks the cardinal signs of
inflammation; pain, heat, redness and swelling[2]. Moreover, the continuous progression
of tissue injury and repair promotes extensive fibrosis that may eventually cause
irreversible tissue dysfunction. This persistent low-grade inflammation has been found
responsible for promoting many diseases, specifically obesity associated insulin resistance
and CRC[3-5].
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Macrophages can enter various tissues in response to chronic inflammation and
assume different functions and phenotypes according to the cues they receive from the
environment[6]. The infiltration of macrophages within tissues is controlled, in part,
through the monocyte chemoattractant protein-1 (MCP-1)[1]. Upon entering the tissue in
response to MCP-1, pro-inflammatory cytokines such as IFN-γ, TNF, or Toll-like receptor
(TLR) ligands, encourage an M1 phenotype while M2 phenotype is promoted upon IL-4,
IL-10, or TGF-β stimulus. M1 macrophages release high levels of pro-inflammatory
cytokines, including tumor necrosis factor-α (TNF-α), MCP-1, IL-6, and inducible nitric
oxide synthase (iNOS) [7]. On the contrary, M2 macrophages have been demonstrated to
express high levels of mannose receptor (CD206), and produce a large amount of IL-10,
and arginase-1[8, 9]. In the context of chronic inflammation, the ratio between M1 and M2
macrophages is constantly shifting during bouts of inflammation followed by periods of
tissue healing. This fluctuation in macrophage subsets throughout the progression of
chronic inflammation makes it unclear which macrophage subsets are truly responsible for
disease progression.

1.2 Inflammation induced colorectal cancer
Colorectal cancer is the third most prevalent cancer as well as the third leading
cause of cancer related deaths. Although, direct etiology is uncertain, there is an increased
risk of colorectal cancer within individuals suffering from chronic inflammatory diseases,
particularly, inflammatory bowel diseases (IBD). As discussed previously, macrophages
can strongly influence both the onset of inflammation within the colon and conversely,
promote tissue remodeling, which can support dysplasia. The intestine is the largest
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reservoir of macrophages in the body [10] where they have a close relationship with
luminal bacteria. [11] Under inflammatory conditions, monocytes are recruited to the
lamina propria and become inflammatory macrophages that secrete cytokines. [12] This
macrophage-induced inflammation mediates many pro-tumoral responses. [13-18] Thus,
it is no surprise that macrophages have been implicated in tumorigenesis given their
propensity to promote inflammation. [18-30]
Although M1 macrophages are heavily involved in initiating colon inflammation,
the resulting M2 macrophage mediated tissue remodeling can trigger tumor growth.
Within this tumor microenvironment, macrophages are the most abundant immune
population. Tumor derived factors such as TGF-β and IL-10 have the potential to polarize
infiltrating monocytes mainly into a M2-like phenotype that can then further promote
proliferation, invasion and metastasis, angiogenesis, and matrix deposition and remodeling
[31]. These macrophages are referred to as tumor-associated macrophages (TAMs). The
majority of studies have reported that high levels of TAMs are associated with poor
prognosis in CRC [32, 33], with just a few reports indicating an association between
macrophage infiltration and increased survival [34, 35]. A crosstalk between TAMs and
cancer cells enhances production of inflammatory cytokines, chemokines, proteases,
growth factors and angiogenesis-related factors [31]. Additionally, these substances
transform the tumor microenvironment to favor the survival, growth and motility of cancer
cells.

Thus, macrophage-induced inflammation mediates many of the pro-tumoral

responses in the tumor microenvironment [13-18]. Given macrophages strong presence
within the tumor microenvironment, targeting TAMs can offer beneficial effects for
inflammation driven cancers.
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1.3 Obesity associated inflammation and insulin resistance
Obesity is considered an epidemic and affects more than 1/3 of the U.S. population.
It is largely defined by two primary characteristics: chronic, low-grade inflammation and
metabolic dysfunction. It is believed that the main driving force behind the development
of type 2 diabetes and insulin resistance is inflammation, particularly macrophage
associated inflammation [36]. Infiltrating immune cells are primarily pro-inflammatory
macrophages, otherwise classified as M1 macrophages which are responsible for adipose
tissue inflammation [37]. Under obese conditions, M1 macrophages may account for
approximately 50% of all adipose tissue cells [37]. Conversely, in the lean condition,
macrophages only account for approximately 10% of all adipose tissue cells, with the antiinflammatory, M2 macrophage phenotype being the most predominant. During the onset
of obesity, the macrophage presence within adipose tissue shifts from M2, which helps
promote homeostasis through efferocytosis, angiogenesis promotion and lipid buffering
toward a more M1 dominant phenotype which increases production of inflammatory
cytokines and reactive oxygen species resulting in non-esterified fatty acid release [38].
More specifically, M1 adipose tissue macrophages secrete the pro-inflammatory cytokines,
TNFα, IL-6 and IL-1β, which act as main effectors of impaired adipocyte function and
have been shown to reduce insulin sensitivity in certain tissues [37, 39-41]. Therefore,
targeting macrophage-associated inflammation may offer potential benefits in preventing
or delaying obesity induced insulin resistance.
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1.4 Sex-Disparities in Obesity-Enhanced Colorectal Cancer.
A sex-specific effect is present in the incidence of obesity in CRC patients. Several
epidemiological studies have demonstrated that obesity increases the risk of and mortality
from CRC in males [42-44]. The relationship in females is somewhat inconsistent, in part
due to a potential protective effect that reproductive hormones have on CRC.

In

postmenopausal women however, this effect may be limited to individuals not currently
using hormone replacement therapy (HRT) [45]. A protective effect of HRT on colon
cancer has been reported in several epidemiological studies [46, 47]. Taken together, these
studies suggest that a woman’s risk of colon cancer is affected by hormonal status. Despite
these findings, the mechanisms linking estrogen and/or progestins to reduced cancer risk
have not been fully elucidated.
The role of estrogen in macrophage polarization under physiological conditions
remains unclear. There is evidence that estrogen inhibits the production of Th1 cytokines,
while stimulating the production of Th2 cytokines [48]. In this case Th2 cytokines
generally promote M2 macrophage polarization however there is little evidence to support
a direct effect of estrogen on macrophage polarization. Taken together, current literature
does not provide a conclusive role for estrogen in CRC and calls for more research to better
understand the mechanism behind this suspected protection. Given the influential role of
macrophages in chronic inflammatory diseases and differential incidence within males and
females, further investigation to test if estrogen has some influence on macrophage
behavior is warranted.
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1.5 Summary
Macrophages play a variety of roles during the development of chronic
inflammation leading to disease. In the context of obesity, M2 adipose tissue macrophages
are most abundant in the lean state but as obesity progresses M1 adipose tissue
macrophages predominate. These M1 macrophages are thought to drive inflammation
induced insulin resistance. Conversely in the context of inflammation associated CRC,
intestinal macrophages are more M1 in the early stages of inflammation but during later
stages as tumors begin to form, M2 like TAMs predominate which is associated with poor
prognosis.

There is further evidence to support that sex disparities within these

inflammatory diseases, may be, in part, associated with sex hormones influence on
macrophage behavior. Therefore, the overall goal of this research is to examine the role of
macrophages in CRC and risk factors associated with CRC including obesity and sex. The
central hypothesis is that macrophage associated inflammation enhances progression of
CRC and this can be exacerbated among obese populations. Further, it is hypothesized that
macrophage associated inflammation may contribute to the sex disparities observed in
obesity and CRC. This hypothesis was tested by pursuing three research aims: 1) to
determine the effect of macrophage depletion on intestinal inflammation, the gut
microbiota profile, and colon tumorigenesis [49]; 2) to determine the effect of macrophage
depletion in diet induced obesity associated inflammation and metabolic dysfunction [50];
and 3) to examine sex-specific differences as they relate to macrophage behavior in
obesity-enhanced CRC.
The purpose of the first study was to examine the role of macrophages in
progression of CRC while also considering the interaction between macrophages and gut
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microbiota in CRC. This was done using the chemically-induced, azoxymethane (AOM)
and dextran sodium sulfate (DSS), model of CRC. In this AOM/DSS model animals
develop tumors following three cycles of a colon irritant, resembling inflammation induced
CRC, such as in IBD patients. We used clodronate filled liposomes to deplete macrophages
during the late stage (week 7) of this model in order to specifically target TAMs rather than
inflammatory macrophages within the early stages [51-53].
In the second study, we sought to examine the role of macrophage associated
inflammation in obesity induced insulin resistance. Utilizing HFD feeding, an obese
phenotype was established prior to depleting macrophages with clodronate encapsulated
liposomes, in order to determine if macrophage depletion could serve as an effective
intervention to reduce obesity-driven adipose tissue inflammation and to ameliorate
metabolic dysfunction.
In the final study, sex differences in obesity enhanced colorectal cancer were
examined. Diet induced obesity was established in male, female, and ovariectomized mice,
prior to injection of MC38 colon cancer cells subcutaneously.

Tumor associated

macrophage phenotype and macrophage associated adipose tissue inflammation were
examined to better understand the role of macrophages in sex specific effects on diet
induced obesity.
Taken together, the studies described offer unique insight into the differential role
that macrophages play in the chronic inflammatory driven diseases of obesity and CRC.
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CHAPTER 2

MACROPHAGE DEPLETION USING CLODRONATE LIPOSOMES
DECREASES TUMORIGENESIS AND ALTERS GUT MICROBIOTA IN
THE AOM/DSS MOUSE MODEL OF COLON CANCER1

1

Bader JE, Enos RT, Velázquez KT, Carson MS, Nagarkatti M, Nagarkatti PS,
Chatzistamou I, Davis JM, Carson JA, Robinson CM, Murphy EA. Macrophage depletion
using clodronate liposomes decreases tumorigenesis and alters gut microbiota in the
AOM/DSS mouse model of colon cancer. Am J Physiol Gastrointest Liver Physiol. 2018
Jan 1;314(1):G22-G31
Reprinted here with permission from publisher
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2.1 Abstract
We examined the role of macrophages in inflammation associated colorectal cancer
(CRC). Given the emerging evidence on immune-microbiota interactions in CRC, we also
sought to examine the interaction between macrophages and gut microbiota. To induce
CRC, male C57BL/6 mice (n=32) received a single injection of azoxymethane (AOM)
followed by three cycles of dextran sodium sulfate (DSS) supplemented water at weeks 1,
4, and 7, respectively. Prior to the final DSS cycle (week 7) and twice weekly until
sacrifice, mice (n=16/group) received either 200l i.p. of clodronate filled liposomes
(CLD) or phosphate buffered saline (PBS) encapsulated liposomes to deplete
macrophages.

Colon tissue was analyzed for polyp burden, macrophage markers,

transcription factors, and inflammatory mediators. Stool samples were collected and DNA
was isolated and subsequently sequenced for 16S rRNA. Clodronate liposomes decreased
tumor number by ~36% and specifically large (≥1mm) tumors by ~36% (p<0.05). This
was consistent with a decrease in gene expression of EMR1 in the colon tissue and polyp
tissue as well as expression of select markers associated with M1 (IL-6) and M2
macrophages (IL-13, IL-10, TGFβ & CCL17) in the colon tissue (p<0.05). Similarly, there
was a decrease in STAT3 and MAPK p38 and ERK signaling in colon tissue. Clodronate
liposomes increased the relative abundance of the Firmicutes phylum (p<0.05) and
specifically Lactobacillaceae and Clostridiaceae families, which have been associated
with reduced CRC risk. Overall, these data support the development of therapeutic
strategies to target macrophages in CRC and provide support for further evaluation of
immune-microbiota interactions in CRC.
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2.2 Introduction
Colorectal cancer (CRC) is the third most common malignancy for men or women.
For CRCs detected in stage I there is a 91% survival rate whereas that drops to 11% if the
cancer is detected in stage IV [54]. As CRC progresses, treatment options become more
limited and some patients with advanced CRC opt for no treatment given the lack of
success of current therapies. Immunotherapy is a relatively recent strategy that has had
some success in treating patients with advanced CRC. However, current immunotherapy
options are limited.

For example, Pembrolizumab, an immune checkpoint inhibitor

targeting PD-1 is limited to patients that have tested positive for specific gene changes [55].
There is a critical need to develop new immunotherapy-based strategies for treatment of
CRC.
Macrophages are the most abundant immune population in a tumor
microenvironment. They are derived from monocytic precursors circulating in blood and
are recruited to the tumor site by chemokines such as MCP-1 and TGFβ [56, 57]. These
recruited monocytes differentiate into mature macrophages within the tumor
microenvironment. While historically it was thought that macrophages possess anti-tumor
functions it is now generally accepted that tumor associated macrophages (TAMs) are
conditioned by the tumor environment and exert pro-tumoral functions. Factors such as
TGF-β and IL-10 have the potential to modulate and polarize monocytes mainly into M2
macrophages that can then promote proliferation, invasion and metastasis, angiogenesis,
and matrix deposition and remodeling [31]. The majority of studies have reported that high
levels of TAMs are associated with poor prognosis in CRC [32, 33] with just a few reports
indicating an association between macrophage infiltration and increased survival [34, 35].
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Understanding the importance of macrophages in CRC is likely to have significant
therapeutic implications.
Increasing evidence implicates gut microbiota in the initiation and progression of
CRC [58]. Mechanistic support for this relationship comes from animal studies; germ-free
status and treatment with wide-spectrum antibiotics results in a significant reduction in
CRC [59, 60]. In humans, CRC-associated microbiome risk profiles have been generally
characterized as changes in certain microbe abundance and/or changes in microbial
diversity. Recent discoveries suggest that immune cells play a pivotal role in this response.
For example, host-derived inflammatory responses are important driving forces that shape
microbial community composition and, when altered, may contribute to dysbiosis and
increased CRC risk [61-63]. Conversely, gut microbes also can influence immune
responses in the colon. A recent study reported that germ-free mice exhibit decreased
populations of intestinal regulatory T cells [64]. Similarly, antibiotic treatment in mice
resulted in reduction of Th17 cells within the colon [65]. Despite the increasing evidence
supporting an immune-microbiota interaction in CRC, there are no studies that have
directly examined the role of macrophages on gut microbiota in a model of CRC.
The purpose of this study was to examine the role of macrophages in progression
of CRC. We also sought to examine the interaction between macrophages and gut
microbiota in CRC. This was done using a chemically-induced model of CRC, namely the
azoxymethane (AOM) and dextran sodium sulfate (DSS) model. In this AOM/DSS model
animals develop tumors due to several gene mutations that are consistent with those seen
in CRC patients [66]. We used clodronate filled liposomes to deplete macrophages [5153]. As we were interested in examining the role of macrophages in progression of
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tumorigenesis (as opposed to initiation), macrophages were depleted during the last cycle
of DSS treatment (i.e. late stage at a time when tumors are already present as confirmed by
our laboratory (unpublished)). Our data indicate that clodronate administration during late
stage tumorigenesis results in a decrease in polyp number, reduced expression of select
macrophage markers, diminished activation of transcription factors known to regulate
carcinogenic processes, and alterations in the gut microbiota profile.

2.3 Materials and Methods
Animals and AOM/DSS model: C57BL/6 (wild-type (WT)) male mice (n=32) were
purchased from Jackson Laboratories. All experimental mice were fed an AIN-76A diet
(Bio-serv) and were provided with water ad libitum for the duration of the experiment. At
8-10 weeks of age, all mice were injected i.p. with a single dose of 10 mg/kg of AOM
(Sigma) designated as week 0. DSS (MP Biochemicals; 36,000-50,000 mw) was dissolved
in filtered drinking water and administered to mice for 7 days during the following weeks:
1 (2% DSS), 4 (1% DSS), and 7 (1% DSS). To deplete macrophages, we administered a
200ul i.p. injection (~1mg) of clodronate encapsulated liposomes (ClodronateLiposomes,
Amsterdam, The Netherlands) beginning at week 6.5 and continuing twice weekly until
sacrifice (CLD).

This dose was selected based on the recommendations of the

manufacturer and previously published literature.

Phosphate buffered saline (PBS)

encapsulated liposomes (ClodronateLiposomes) were administered in the same manner to
the vehicle control group (VEH). After 12 weeks, mice (VEH & CLD) were sacrificed,
colon contents were collected for microbiota profiling, colons were dissected, and polyps
were counted using a stereoscope. For a subset of samples (n=4-8) the distal portion of the

13

colon was fixed in 4% paraformaldehyde, paraffin embedded, and sectioned for
Hematoxylin & Eosin (H&E) staining. Polyps were removed from the remaining colon
tissue and flash frozen for RT-PCR analysis. The remaining colon tissue was then divided
into two pieces for western blot and RT-PCR analysis. The Institutional Animal Care
Committee of the University of South Carolina approved all the animal experimentation.
Morphometric measurements, food and water intake: Body weight, and food and
water intake were monitored weekly over the duration of the experiment.

Body

composition was assessed before AOM injection and prior to sacrifice (week 12) via dualenergy x-ray absorptiometry (DEXA, Lunar PIXImus) as previously described [67].
Symptom Severity: Symptom score was evaluated twice a week beginning at the
first cycle of DSS exposure. Briefly, animal health was monitored by combining the scores
of weight loss (WL) (>5%WL=0; 6-10%WL=1; 11-15%WL=2); fecal consistency
(pellet=0; pasty=2; liquid=4); and blood in stools (assessed with hemoccult kit negative=0,
positive=2, and gross bleeding=4) [68].
Gene expression: Quantitative RT-PCR (ABI-7300) was performed in both the
polyp and colonic tissue after RNA isolation with trizol reagent and purification from DSStreated tissues as described in detail [69]. Sample ct values calculated as relative to 18S
rRNA internal control and normalized to vehicle control. The following Taq primers from
Applied Biosystems were used: MCP-1, TNFa, IL-6, EMR1, NOS2, IL-10, IL-12a, IL-23,
IL-13, TGFb, Arg1, and CCL17.
Western blot analysis: The frozen colons were homogenized in mueller buffer [70]
and total protein was determined via the Bradford method. All samples were run in
triplicate on the same plate with a CV of less than 3%. Equal amounts of crude protein
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homogenates (10-40 μg) were fractioned on hand-casted 6.5-12% SDS-polyacrylamide
gels and electrophoretically transferred to a PVDF membrane using a Genie Blotter (IDEA
Scientific, Minneapolis, MN). Membranes were stained with a Ponceau S solution to
verify equal protein loading and transfer efficiency. Subsequently, membranes were
blocked for one hour in 5% milk in Tris-buffered saline, 0.1% Tween-20 (TBST). Primary
antibodies were diluted 1:1,000 in 5% milk-TBST or 5% BSA-TBST solution according
to antibody specifications for either a 1 hour incubation at room temperature [Cell
signaling, Danvers, MA: total ERK (#4676) total Stat 3 (#4904) and total p38 (#8690)] or
overnight incubation at 4C [Cell signaling: total (#8242) and phosphorylated (Ser536)
NFκB p65 (#3033), phosphorylated (Thr180/Tyr182) p38 (#4631), phosphorylated ERK
(#4376), phosphorylated Stat 3 (y705) (#9138)]. An anti-rabbit (Cell signaling: #7047) or
anti-mouse (Cell Signaling: #7076) IgG horseradish peroxidase conjugated secondary
antibody was diluted 1:2000 in 5% milk and incubated for one hour at room temperature.
An enhanced chemiluminescent substrate for detection of horseradish peroxidase (Thermo
Scientific, Watham, MA) was used to visualize the antibody-antigen interaction.
Autoradiography films were scanned and blots were quantified using scientific imaging
software (Image J). After completion of the western blot, all membranes were stained with
Amido black, and the densitometry of each lane was calculated using Quantity One
Software (Bio-Rad, Hercules, CA) allowing for total protein normalization. This method
of normalization has been shown to be more accurate than typically used loading controls
[71].
Histology: Paraffin block sections of the distal colon were stained with H&E and
subsequently evaluated blindly by a pathologist (I.C.) and characterized according to the
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severity of tumor dysplasia when a tumor was present in the section; low-grade dysplasia
(LGD) or high-grade dysplasia (HGD).
Microbiome Analysis: Following sacrifice, feces from the colon was removed, snap
frozen and stored at -80°C until analysis. Microbial DNA was isolated from feces using a
QIAamp Fast DNA Stool Mini Kit (QIAGEN #51604) according to manufacturers’
instruction. The DNA concentration was determined using a Nanophotometer Pearl,
diluted to 5 ng/ul in 10 mM Tris Buffer pH 8.5 and stored at -20°C until analysis.
Amplification of the 16S rRNA V3-V4 hypervariable region was carried out using the 16S
V3

314F

forward

(5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
3′)

and

V4

805R

reverse

primer

(5′GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCT
AATCC3′) with added Illumina adapter overhang nucleotide sequences [72]. The PCR
conditions used were 3 min at 95 °C followed by 25 cycles of 30 s at 95 °C, 30 s at 55 °C
and 30 s at 72 °C, and a final extension at 72 °C for 5 min. Each reaction mixture (25 μl)
contained 50 ng of genomic DNA, 0.5 μl of amplicon PCR forward primer (0.2 μM), 0.5
μl of amplicon PCR reverse primer (0.2 μM) and 12.5 μl of 2× KAPA Hifi Hot Start Ready
Mix. Each reaction was cleaned up using Agencourt AMPure XP beads. Attachment of
dual indices and Illumina sequencing adapters was performed using 5 μl of amplicon PCR
product DNA, 5 μl of Illumina Nextera XT Index Primer 1 (N7xx), 5 μl of Nextera XT
Index Primer 2 (S5xx), 25 μl of 2× KAPA HiFi Hot Start Ready Mix, and 10 μl of PCRgrade water. Amplification was carried out under the following conditions: 3 min at 95
°C, followed by 8 cycles of 30 s at 95 °C, 30 s at 55 °C, and 30 s at 72 °C, and a final
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extension at 72 °C for 5 min. Constructed 16S metagenomic libraries were purified with
Agencourt AM Pure XP beads and quantified with Quant-iTPicoGreen. Library quality
control and average size distribution were determined using an Agilent Technologies 2100
Bioanalyzer. Libraries were normalized and pooled to 40 nM based on quantified values.
Pooled samples were denatured and diluted to a final concentration of 6 pM with a 30%
PhiX (Illumina) control. Amplicons were subjected to pyrosequencing using the MiSeq
Reagent Kit V3 in the Illumina MiSeq System.
The online 16S analysis software from NIH (https://nephele.niaid.nih.gov/) was used to
analyze sequencing data collected on the Illumina Miseq.

FASTQ sequences were

uploaded to Nephele and the 16S metagenomics application was executed. The groups of
related DNA sequences were assigned to operational taxonomic units (OTUs), and output
files were analyzed to determine gut microbial composition.
Statistics: Data were analyzed using commercially available statistical software:
Prism 5 and SigmaStat (GraphPad Software). Data were analyzed using an unpaired
Student t-test or Fisher’s exact test (categorical data). Any statistical test that did not pass
the equal-variance test (Bartlett’s test for equal variances) was log transformed and then
re-analyzed. Data are presented as the mean ± SEMs and the level of significance was set
at p<0.05.

2.4 Results
Effects of clodronate administration on morphometric characteristics in AOM/DSS treated
mice.
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Body weights and symptom scores over the course of the 12-week AOM/DSS
protocol are presented in Figure 2.1. The dashed line represents the initiation of clodronate
treatment at week 6.5 and twice weekly i.p. injections for the duration of the study. There
was no difference in body weight between treatment groups prior to clodronate
administration; however, body weight was reduced in clodronate treated mice following
administration at weeks 7-12 (p=0.079, 0.066, 0.015, 0.023, 0.002, and 0.007 respectively
(Figure 2.1A)). Despite the decrease in body weight, there was no significant difference
in symptom scores between treatment groups over the course of the experiment (Figure
2.1B). It is important to note that mice from each treatment had similar starting body
weights (p=0.218) ensuring that both groups received similar doses of the carcinogen AOM
(Figure 2.1A). Additionally, both groups consumed equal amounts of total DSS over the
course of the 12-week protocol (p=0.923) (data not shown). Regarding food intake,
clodronate treatment significantly decreased consumption compared to control mice and
this was consistent with a decrease in lean mass, fat mass and fat% in the DEXA body
composition measurements (Figure 2.1 C-E).
Effects of clodronate administration on colon polyps and colon inflammation
Clodronate administration resulted in a significant reduction in overall polyp
number (p=<0.001). When polyps were stratified by size, we found a reduction in large
polyps greater than or equal to 1 mm (p=0.012) and a slight, but non-significant, reduction
in small polyps less than 1 mm (p=0.100) following clodronate treatment (Figure 2.2A-B).
Following histological analysis, we did not document any colon carcinomas in either
group. However, it should be noted that only the distal colon was included in this analysis
and for a small subset of mice (n=4-8). To further explore the effects of clodronate
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administration on tumorigenesis, distal colon polyps were evaluated for dysplasia and
quantitatively represented as low-grade dysplasia (1) or high-grade dysplasia (2). There
was no significant difference in severity of dysplasia between treatment groups with both
groups exhibiting high-grade dysplasia in polyps scored (Figure 2.2C-D). Similarly,
histological inflammation revealed no differences between the groups. To further evaluate
the CRC phenotype, spleen and colon weight and colon length to width ratio were
determined. The ratio of spleen to body weight and colon weight was reduced in the
clodronate treated group (p=0.007 and 0.152 respectively), which is consistent with the
decreased tumor number (Figure 2.2E-F). However, there was no difference in the colon
length to width ratio (Figure 2.2G).
Effects of clodronate administration on cytokine and cell marker expression in the colon
In addition to histological evaluation of the colon, gene expression profiles via
qPCR of cytokine and macrophage cell markers for both colon and colon polyp tissue are
shown in Figure 2.3. Within the clodronate treated group, the macrophage cell marker
F4/80 was significantly reduced in both colon and colon tumor tissue (p=<0.001 and
p=0.024, respectively) confirming that clodronate was effective at depleting F4/80 positive
cells in both the target tissue and tumor (Figure 2.3A). This was consistent with a decrease
in MCP-1, a strong macrophage chemoattractant, in the colon tissue of clodronate treated
mice (p=0.019) (Figure 2.3B). Despite the reduction in the macrophage cell marker F4/80
and macrophage chemoattractant, we were not able to characterize this decrease as M1 or
M2 phenotype specific as no statistically significant differences were found for NOS2 and
Arg 1, M1 and M2 markers, respectively (p=0.643 and p=0.389). However, within the
colon tissue, anti-inflammatory M2 associated cytokines including IL-13, TGF-, IL-10,

19

and CCL-17 were significantly reduced (p=<0.001, 0.002, <0.001, and 0.009, respectively)
with clodronate treatment. Aside from IL-6 (p=0.01) there were no significant differences
in pro-inflammatory M1 associated cytokines. Despite the reduction in F4/80 expression,
there were no significant differences in macrophage marker or cytokine expression in the
colon tumors (Figure 2.3C). To confirm that changes in gene expression are reflective of
changes in downstream signaling pathways, western blot analysis was performed and
results are illustrated in Figure 2.4. Consistent with reduced expression of IL-10 and IL-6
in the clodronate treated group, was activation of the downstream transcription factor
STAT3 (p=0.026 and 0.005, respectively). There was also a significant reduction in the
activated MAPK signaling molecules p38 and ERK for the clodronate treated group
(p=0.003 and p=<0.001, respectively). However, there was no significant difference in
NFKb expression for phosphorylated, total or calculated ratio, between the groups.
Effects of clodronate administration on microbiota composition
Stool samples were collected at sacrifice and 16S microbial rRNA sequencing was
performed (Figure 2.5). Relative abundance of OTUs in the Firmicutes phylum were
significantly increased in the clodronate treated group compared with the control group
(p=0.02) (Figure 2.5A). Specifically, within the Firmicutes phylum, the Lactobacillaceae
and Clostridiaceae families were significantly increased in the clodronate treated group
contributing to the respective changes at the Phylum level (p=0.04 and 0.009, respectively).
Additionally, there was a slight increase in Erysipelotrichaceae family in the clodronate
treated group although not statistically significant (p=0.08) (Figure 2.5B).

Despite

differences in relative abundance within phyla and families, there were no significant
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differences between alpha or beta diversity, as shown through Chao1 index and weighted
UniFrac PCA plots, respectively (Figure 2.5C-D).

2.5 Discussion
TAMs have been associated with CRC progression, metastasis, and poor prognosis
[33, 73-75].

However, this relationship is complex given that different macrophage

subsets are likely to have stage-specific roles in CRC progression. Using the AOM/DSS
mouse model of CRC we sought to better understand the role of macrophages in tumor
progression. As emerging evidence implicates immune-microbiota interactions in CRC
we also sought to examine the interaction between macrophages and gut microbiota in
CRC. Our data indicate that clodronate administration, a well-established method to
deplete macrophages [51-53], during late stage tumorigenesis results in a decrease in polyp
number, reduced expression of select macrophage markers, diminished activation of
transcription factors, and alterations in the gut microbiota profile.
We used clodronate liposomes to deplete macrophages during the final cycle of
DSS (i.e. at a time when polyps are present) to specifically determine their role in tumor
progression as opposed to tumor initiation. This approach was employed in order to
establish the efficacy of targeting macrophages for treatment of CRC. We report a
significant reduction in overall polyp number (36%) as well as the number of large polyps
(36%). However, as baseline polyps (i.e. prior to clodronate treatment) were not evaluated
we were not able to determine whether clodronate treatment decreased size of existing
polyps and/or growth of new polyps. These findings are consistent with a previous study
from our laboratory showing that deletion of MCP-1, the most important chemokine for
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macrophage recruitment, results in a decrease in polyp number and size in in the ApcMin/+
mouse model of intestinal tumorigenesis. Zhao et al., reported similar findings with a
~45% percent reduction in AOM/DSS induced tumorigenesis when macrophages were
depleted during both the initiation and progression of tumorigenesis [76]. However, unlike
the current study, stage-specific effects could not be determined from these reports.
Despite the differences in polyp number and size, we were not able to detect a difference
in severity of dysplasia or histological inflammation between treatment groups. This may
not be entirely surprising given that clodronate administration was performed at a time
when mice are likely to already exhibit high dysplasia and this analysis was performed on
a small sample size. Similarly, and likely for the same reasons, we were not able to identify
any differences in disease activity index scores. Contrary to what would be expected with
reduced tumorigenesis, the clodronate treated group had a decrease in body weight and
body fat percent; typically, body weight loss or fat loss is associated with worsened
outcome in this model. However, given the fact that tumorigenesis was decreased with
clodronate and that we (unpublished) and others [77] have found a decrease in food
consumption and/or body weight with clodronate/macrophage depletion [77, 78], we
suggest that this is an effect of clodronate treatment independent of the tumorigenesis
outcomes. Given this, it is certainly possible that the reduced tumorigenesis associated
with clodronate treatment could be explained, or partially explained, by the reduction in
food intake and subsequent decrease in body weight as there is evidence that caloric
restriction reduces tumorigenesis [79]. Nonetheless we believe that our findings set the
stage for the development of strategies to target macrophages to treat CRC.
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Although clodronate liposomes are a well-established method of macrophage
depletion in the colon [51-53], we wanted to confirm successful depletion in our hands and
further establish whether it was effective at depleting macrophages in the tumor
microenvironment. Indeed, we show that compared to PBS, clodronate-filled liposomes
successfully decreased expression of F4/80+, a pan macrophage marker, within the colon
tissue and corresponding polyp tissue (Figure 2.3A); although it appeared more effective
in the colon tissue. This is not surprising given the route of administration and mechanism
of action of clodronate [51-53]; macrophages in the intestinal tissue would likely be more
available to uptake the liposomes than those deep within the tumor tissue, clodronate does
not result in complete depletion of macrophages, and there is evidence to suggest that
TAMs may lose their phagocytic activity as tumorigenesis progresses [80]. To further
characterize the effects of clodronate on macrophages in the colon and tumor
microenvironment we examined M1 and M2 macrophage associated markers. In general,
and as for F4/80, clodronate liposomes were more effective at altering expression of
macrophage markers in the colon tissue as opposed to the polyp tissue. In the colon tissue
clodronate decreased expression of select M1 (IL-6) and M2 (IL-13, IL-10, TGFβ and
CCL17) associated markers along with the macrophage chemoattractant MCP-1 indicating
its non-selectivity for macrophage phenotype.

Thus, a simultaneous/non-specific

reduction in markers associated with both M1 and M2 macrophage populations can reduce
tumorigenesis. Interestingly, we found an increase in IL-13 in the tumor microenvironment
in the clodronate treated group. IL-13 has been shown to be increased in certain cancers
and can influence polarization of TAMs [81, 82]. Therefore, it is possible that the spike in
IL-13 is compensatory production of IL-13 by T helper 2 cells in response to the overall
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decrease in F4/80 positive cells. While we and others have successfully used clodronate
to deplete macrophages, the possibility of also impacting dendritic cells has been reported
[51] and these cells can influence CRC [83]. Thus, we cannot rule out a role for dendritic
cells in this model. While we did not measure systemic cytokine levels in this study it is
certainly possible that a reduction in circulating inflammatory mediators by clodronate [84]
also may be contributing to the reduced tumorigenesis in this model. Although these
findings should be validated using FACS, we conclude that clodronate administration has
beneficial effects on tumorigenesis and that even larger effects may be possible if M2
macrophages can be selectively depleted in the tumor microenvironment.
Given the significant effects of clodronate administration on cytokines in the colon
tissue we next examined downstream transcription factors in the normal tissue. STAT3, a
major mediator of IL-6 and IL-10 signaling, was reduced following clodronate treatment
consistent with the decrease in mRNA expression of IL-6 and IL-10. STAT3 has been
reported to be deregulated in many cancers including CRC and has been associated with
metastasis and poor prognosis [85, 86]. p38 MAPK also was decreased in clodronatetreated mice. Although the p38 pathway is often related to pro-apoptotic effects and tumor
suppressor activity in some tissues, it has been suggested that p38 acquires an oncogenic
role particularly in established malignancies [87]. Similarly activated ERK MAPK was
decreased in the clodronate-treated group. Mutations leading to constitutive activation of
ERK pathways are found in >40% of CRC patients and significantly contribute to tumor
formation and progression [87, 88]. In support of our findings, Chiacchiera et. al. has
shown that combined inhibition of p38 and ERK MAPK pathways efficiently reduces the
volume of xenografted tumors and AOM/DSS-induced tumors in vivo [88]. On the other
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hand, there was no change in activated NF-κB with clodronate treatment although NFκB
has been associated with CRC [89]. The failure to detect a difference in NFκB may not be
surprising as there was no difference in TNF-α, an activator of the canonical NFκB
pathway, and IL-1β was not measured. Alternatively, the failure to see changes in activated
NFκB may reflect averaging of this signal in whole colon comprised of an admixture of
cells. While not performed for the current study given limitations in tissue, it would have
been useful to double-stain colon sections for both p-NFκB p65 and a macrophage marker
to determine whether macrophage NFκB signaling is altered. Even so, these data provide
strong support for targeting macrophages to prevent the activation of transcription factors
associated with CRC.
Emerging evidence implicates immune-microbiota interactions in CRC [90,
91]. Therefore, we next examined the effects of clodronate treatment on the gut microbiota
profile. Relative abundance of OTUs in the Firmicutes phylum was significantly higher in
the clodronate-treated group. Firmicutes, represent one of the two most abundant phyla in
the gut microbiota and therefore a change within this phylum can have profound effects on
intestinal homeostasis. In fact, decreases in Firmicutes have been reported in inflammatory
bowel disease and CRC [90, 92-95]. The anti-cancer effects of Firmicutes are likely due,
at least in part, to the production of short chain fatty acids, specifically butyrate, which has
documented effects on CRC. Within this phylum, Lactobacillaceae represent the known
probiotic Lactobacillus, and Clostridiaceae contain strong butyrate producers in the
clusters IV and XIVa. These bacteria were significantly increased in the clodronate treated
group. Despite differences in relative abundance within phyla and families, there were no
significant differences between alpha or beta diversity, as shown through Chao1 index and
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weighted UniFrac PCA plots, respectively. This indicates that overall alpha and beta
diversity within stool was unaffected by clodronate treatment. Thus, our data suggest that
macrophages may be facilitating the change in Firmicutes abundance. However, these
findings should be interpreted with caution as it is unclear whether the change in Firmicutes
is a direct result of macrophage depletion or an indirect effect of the decrease in
tumorigenesis. Contributions from both explanations are also a possibility. Nonetheless,
we show a strong association between lower frequency of macrophages, increased
Firmicutes, and decreased tumorigenesis in this model. Together, this supports further
evaluation of macrophage-microbiota interactions in CRC.
In summary, we found that clodronate administration during late-stage
tumorigenesis is effective at reducing tumor growth. This was associated with a decrease
in select M1 and M2 macrophage markers and chemokines in the colon tissue and a
decrease in transcription factors that are linked to CRC. Additionally, the clodronatetreated group was found to have an increased abundance of Firmicutes, a phylum with
documented anti-tumorigenic effects. Overall, these data support the development of
therapeutic strategies to target macrophages in CRC and provide further support for further
evaluation of immune-microbiota interactions in CRC.
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2.6 FIGURES & LEGENDS

Figure 2.1: Effects of late stage clodronate administration on morphometric characteristics
following azoxymethane (AOM) and dextran sulfate sodium (DSS) treatment. The dashed
line represents the initiation of clodronate treatment at week 6.5 and twice weekly i.p.
injections for the duration of the study. A: Mouse body weight measurements through
AOM/DSS protocol and clodronate treatments. B: Symptom score (body weight loss +
blood in stool + diarrhea). C: Measured weekly food consumption represented as grams of
food per mouse in cage per day. D and E: Body Composition measure via Dual-Energy Xray Absorptiometry (DEXA) for lean mass, fat mass and fat %. Values are means ± SE;
n=16 mice per group. *P < 0.05. ^P < 0.10 unpaired student t-test.

27

Figure 2.2: Effect of clodronate administration on colon polyps and dysplasia. A and B:
Polyp count and size after AOM/DSS treatment. C: Representative hematoxylin-eosin
stained sections of distal colon tumor exhibiting high grade dysplasia after AOM/DSS
treatment (10X magnification with 20X in upper right box, indicating that dysplastic cells
are limited to the mucosa and do not penetrate through the muscularis mucosa). D:
Histology evaluation of distal colon tumors (quantitatively represented as low grade
dysplasia (1) or high grade dysplasia (2) n=4-8 colons) E: Ratio of spleen weight (mg)/
mouse body weight (g) following AOM/DSS treatment. F: Colon weight (after feces
removed). G: Colon length to width ratio. Values are means ± SE; n=16 mice per group
unless indicated. *P < 0.05. unpaired student t-test.
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Figure 2.3: Effect of clodronate administration on gene expression in colon and colon polyp
tissue. A-C: Quantitative RT-PCR assessment of gene expression in colon and colon tumor
tissue. Ct values relative to 18s rRNA internal control and normalized to vehicle control
group. Values are means ± SE; n=9 mice per group for colon tissue and n=7 mice per group
for colon polyp tissue. *P < 0.05. unpaired student t-test.
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Figure 2.4: Effect of clodronate administration on protein expression in colon tissue. A:
Western blot and corresponding amido black membrane stain of colon tissue. B:
Quantitative intensity of densitometry relative to total protein normalized to vehicle
control. Ratio= total/phosphorylated. Values are means ± SE; n=9 mice per group. *P <
0.05. unpaired student t-test.
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Figure 2.5: Effects of clodronate administration on microbiota composition in stool. A:
Relative abundance of OTU in bacterial Phylum following AOM/DSS treatment. B:
Composition of Families within the Firmicutes phylum (families with abundance less than
0.001 are not shown). C: Rarefraction curve within-sample Chao1 (Alpha Diversity). D:
Principal Coordinates Analysis plot of (Beta Diversity) distance between samples matrix.
Text in bold indicate significant difference. *p <0.05. n= 10 mice per group.
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CHAPTER 3

REPEATED CLODRONATE-LIPOSOME TREATMENT RESULTS IN
NEUTROPHILIA AND IS NOT EFFECTIVE IN LIMITING OBESITYLINKED METABOLIC IMPAIRMENTS2

2

Bader JE, Enos RT, Velázquez KT, Carson MS, Sougiannis AT, McGuinness OP,
Robinson CM, Murphy EA. Repeated clodronate-liposome treatment results in
neutrophilia and is not effective in limiting obesity-linked metabolic impairments. Am J
Physiol Endocrinol Metab. 2019 Mar 1;316(3):E358-E372
Reprinted here with permission from publisher
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3.1 ABSTRACT
Objective: Depletion of macrophages is thought to be a therapeutic option for
obesity-induced inflammation and metabolic dysfunction.

However, whether the

therapeutic effect is a direct result of reduced macrophage-derived inflammation or
secondary to decreases in fat mass is controversial as macrophage depletion has been
shown to disrupt energy homeostasis. This study was designed to determine if macrophage
depletion via clodronate-liposome (CLD) treatment could serve as an effective intervention
to reduce obesity-driven inflammatory and metabolic impairments independent of changes
in energy intake.
Methods: Following 16 weeks of high-fat diet (HFD) or AIN-76A control diet
(LFD) (n=30/diet treatment), male C57BL/6J mice were assigned to either a CLD or PBSliposome-treatment (n=15/group) for 4 weeks. Liposomes were administered bi-weekly
via intraperitoneal injections (8 administrations in total). PBS-liposome-treated groups
were pair-fed to their CLD-treated dietary counterparts. Metabolic function was assessed
pre- and post- liposome treatment. Adipose tissue as well as liver were investigated for
macrophage infiltration and the presence of inflammatory mediators. Additionally, a
complete blood count was performed.
Results: CLD treatment reduced energy intake.

When controlling for energy

intake, CLD treatment was unable to regress metabolic dysfunction or Non-AlcoholicFatty-Liver Disease, and impaired adipose tissue insulin action. Moreover, repeated CLD
treatment induced neutrophilia, anemia, increased adipose tissue mRNA expression of the
pro-inflammatory cytokines, IL-6 and IL-1β, and augmented circulating IL-6 and MCP-1
concentrations (p<0.05).
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Conclusion: This study suggests that the repeated administration of CLD treatment
to deplete macrophages attenuates obesity by limiting energy intake. Moreover, after
controlling for the benefits of weight loss, the accompanying detrimental side effects limit
regular CLD treatment as an effective therapeutic strategy

3.2 INTRODUCTION
Obesity has been established as a public health concern given the condition’s link
to increased health care costs, morbidity, and mortality [96]. The underlying cause of
obesity is rooted in a lack of physical activity and an excessive intake of energy-dense
foods resulting in the obese phenotype. This phenotype is largely defined by two primary
characteristics: chronic, low-grade inflammation and metabolic dysfunction. Although it
has been established that these two processes are linked, the degree to which one process
regulates the other is still not completely understood. It is believed that a main driving
force behind the development of type 2 diabetes and insulin resistance is inflammation
[36]. Thus, therapies designed at combating obesity-associated inflammation may protect
against the obesity-associated metabolic diseases.
Many different factors are thought to play a role in obesity-associated inflammation
including, but not limited to, changes in the gut microbiota, the gut-brain axis, and nonalcoholic-fatty-liver-disease (NAFLD) [97, 98]. However, the immune cells primarily
responsible for adipose tissue inflammation are

infiltrating pro-inflammatory

macrophages, otherwise classified as M1 macrophages [37]. Under obese conditions,
macrophages, predominately of the M1 phenotype, may account for approximately 50% of
all adipose tissue cells [37]. This is in stark contrast to the lean condition, in which
macrophages only account for approximately 10% of all adipose tissue cells, with the anti34

inflammatory, M2 macrophage phenotype being the most predominant. In addition to
clearing dead adipocytes, M1 macrophages secrete a variety of pro-inflammatory
cytokines, including TNF-α, a cytokine known to negatively impact insulin signaling [39].
As such, depletion of macrophages to reduce macrophage-derived adipose tissue
inflammation has been investigated as a potential therapeutic. Depletion of macrophages
in an obese setting reduces adipose tissue inflammation and improves insulin sensitivity
[99, 100]. Macrophage depletion has also been shown to reduce energy intake [101] and
body weight [101-104], and it is well known that energy restriction can attenuate
inflammation and improve metabolic function [105-108]. Whether the beneficial impact
of macrophage depletion extends beyond weight loss has not been examined.
Therefore, through the utilization of pair-feeding, our study was designed to
determine if macrophage depletion could serve as an effective intervention to reduce
obesity-driven adipose tissue inflammation and improve metabolic dysfunction beyond the
weight loss seen with reduced energy intake.

3.3 METHODS
Animals: Male WT C57BL/6J mice were purchased from the Jackson Laboratories
(Bar Harbor, ME) and cared for at the Animal Resources Facility at the University of South
Carolina. Mice (n=15/group) were housed 5 per cage, maintained on a 12:12-h light-dark
cycle in a low stress environment (22°C, 50% humidity, low noise) and given water ad
libitum. Principles of laboratory animal care were followed, and the Institutional Animal
Care and Usage Committee of the University of South Carolina approved all experiments.
Diets: At 6 weeks of age, mice were randomly assigned to either control purified
AIN-76A low-fat diet (LFD) (3.77 kcal/g) or a purified HFD (40% of total kcals from fat;
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4.57 kcal/g) designed to mimic the standard American diet (BioServ, Frenchtown, NJ,
USA). We have used this diet in several of our previous investigations [67, 109-113].
Mice were initially provided the respective LFD or HFD for 16 weeks at which time
baseline body composition (DEXA) and metabolic tests were administered. Based upon
these outcomes, mice within each diet were separated into one of four treatment groups
(LFD phosphate-buffered saline (PBS)-encapsulated liposomes, HFD PBS-encapsulated
liposomes, LFD clodronate (CLD)-encapsulated liposomes, and HFD CLD-encapsulated
liposomes) to match body weight and composition within each dietary treatment.
Subsequently, mice continued their respective diets (LFD or HFD) for another 4 weeks.
Thus, in total, mice consumed diets for 20 weeks.
Clodronate treatment & pair feeding: To deplete adipose tissue macrophages, a
200 μl IP injection (~1mg) of CLD-encapsulated liposomes (ClodronateLiposomes,
Netherlands) was administered twice a week beginning at week 16 of dietary treatment (8
injections in total) until sacrifice at week 20. The selection of this dose of CLD utilized
was based upon pilot work that we conducted. IP administration of CLD liposomes was
chosen as this has previously been shown to be a more effective means of depleting adipose
tissue macrophages compared to intravenous (IV) administration [114]. We had initially
used the manufacturer’s recommended dose of 0.05 mg/g body weight. However, the dose
was scaled down to ≈0.03 mg/g body weight in an attempt to lessen toxicity, but still elicit
significant macrophage depletion as we have previously shown with respect to colonic
macrophages [49]. Administration of CLD treatment was initiated after 16 weeks of HFDfeeding, as we have previously shown this length of feeding induces an obese phenotype
characterized by adipose tissue inflammation with significant adipose tissue macrophage
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recruitment and metabolic dysfunction [67, 109].

PBS-encapsulated liposomes

(ClodronateLiposomes, Netherlands) were administered in the same manner as CLD
liposomes to serve as a control. The sample size in the LFD CLD and HFD CLD groups
was reduced to 9 and 14 mice, respectively, due to apparent toxicity of CLD treatment. In
our unpublished and published [49] experiments, we have found that macrophage depletion
reduces energy intake. This is in accordance with another published paper, which showed
that macrophage depletion (via the use of the diphtheria toxin) resulted in a significant
reduction in energy intake [101]. Given this, PBS treated mice were pair-fed to their CLDtreated counterparts so as not to allow energy intake to be a potential confounding factor
on the outcomes of the study. As the number of mice in each cage was equal across
treatment groups, pair feeding calculations were determined by measuring the food
consumption of CLD-treated animals by averaging the food intake/cage each day prior to
administering food to the counterpart PBS-treated groups. For example, if the 3 CLD HFD
cages consumed 15, 16, and 16.4 grams of food over a 24-hour period, the average of this
food consumption (=15.8 grams) was provided to each of the 3 PBS HFD cages.
Body weights, energy intake, and body composition: Body weight was monitored
on a weekly basis throughout the study. Energy intake was monitored on a weekly basis
prior to CLD treatment and on a daily basis upon the commencement of CLD treatment for
pair-feeding purposes.

Energy intake was calculated by dividing the total food

consumption in grams/cage/week/mouse multiplied by the energy density/gram of the
respective diet. Body composition was assessed before and after CLD treatments (weeks
16 and 20). For this procedure, mice were placed under brief anesthesia (isoflurane
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inhalation) and were assessed for lean mass, fat mass, and body fat percentage via dualenergy X-ray absorptiometry (DEXA) (Lunar PIXImus, Madison, WI).
Metabolism: Metabolic parameters were assessed pre (16 weeks of dietary
treatment) and post CLD treatment (20 weeks of dietary treatment/4 weeks of CLD
treatment). After a five-hour fast, blood samples were collected from the tip of the
tail. Blood glucose concentrations were determined in whole blood using a glucometer
(Bayer Contour, Michawaka, IN). Collected blood was centrifuged at 4,000 rpm for 10
min at 4°C. Plasma was aliquoted and stored at -80°C until analysis. Plasma insulin
concentrations were analyzed according to the manufacturer’s instructions using a mouse
insulin ELISA kit (Mercodia Inc., Winston Salem, NC). For glucose tolerance tests
(GTTs) and insulin tolerance tests (ITTs), mice were fasted for 5 hours and glucose or
insulin was administered (IP) at a dose of 2 g/kg or 0.75 U/kg lean mass, respectively.
Blood glucose concentrations (tail sampling) were measured intermittently over a two hour
period (0, 15, 30, 60, 90, and 120 minutes) for GTTs and intermittently over a one-hour
period (0, 15, 30, 45, and 60 minutes) for ITTs using a glucometer (Bayer Contour,
Michawaka, IN). Area under the curve (AUC) was calculated using the trapezoidal rule.
Fasting serum was collected for free-fatty acid (FFA) analysis at the 0- and 30-minute time
point of the post-CLD treatment ITT to assess insulin’s ability to inhibit lipolysis. FFAs
were analyzed using a commercially available kit according to the manufacturer’s
instructions (Wako Diagnostics, Richmond, VA).
Tissue collection: After 20 weeks of dietary treatment (4 weeks after CLD treatment), mice
were sacrificed via isoflurane inhalation for tissue collection. An aliquot of whole blood
taken from the inferior vena cava was analyzed for hematology analysis using a VetScan

38

Hm5 (Abaxis, Union City, CA). The remaining blood was spun at 4,000 RPM x 10 min
and plasma was stored -80°C. Epididymal, mesentery, and peri-renal fat pads, as well as
the liver were removed, weighed, and immediately snap-frozen in liquid nitrogen and
stored at −80°C or fixed in 4% formalin until analysis.
Hepatic lipid content and alanine transaminase activity (ALT) assay: Lipids were
isolated from the liver utilizing a modified Folch extraction method and were quantified
gravimetrically, as previously described [109, 111, 112, 115, 116]. Plasma ALT activity
was assessed using an Infinity ALT liquid reagent (Thermo Fisher, Middletown, VA)
following the manufacturer’s instructions.
Adipose tissue hydroxyproline assessment: In order to assess the impact of
macrophage depletion on adipose tissue fibrosis, epididymal adipose tissue hydroxyproline
content (an indirect method for assessing collagen deposition[117]) was examined. Due to
limitations in the amount of available epididymal adipose tissue, this assay was limited to
the adipose tissue of HFD groups only. Briefly, 100-200 mg of epididymal adipose tissue
was acid hydrolyzed overnight at 110ºC using 6N HCL. The solution was then centrifuged
(10 min x 10,000 RPM) and the resulting supernatant was collected and dried under
nitrogen gas.

Subsequently, the dried extract was incubated with 0.625 mLs of a

chloramine-T solution for a 30 minute period followed by the addition of 0.625 mLs of
Ehrlich’s solution as previously described [118]. Samples were then incubated for 20 min
at 65ºC, cooled in room temperature water, and then transferred to a 96-well microplate
and read using a spectrophotometer at 550 nm. Hydroxyproline purchased from Sigma
Aldrich (St. Louis, MO) was used to create a standard curve. Total hydroxyproline content
was normalized to the epididymal adipose tissue weight originally used.
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Adipose Tissue and Liver Histology: Formalin-fixed tissues were embedded in
Paraffin blocks and sectioned. The epididymal and peri-renal fat pads and livers were
stained with H&E.

Representative images were taken at 20x and 100x.

For

immunofluorescent and immunohistochemistry staining, the antibodies, antibody
dilutions, and antigen-retrieval methods are provided in Table 1. For negative controls, a
serial section was assayed exactly the same as the treated-section minus the primary
antibody.
Quantitative real-time RT-PCR: RNA was isolated from epidydimal and peri-renal
adipose tissue depots as well as liver using an RNeasy Lipid Tissue Mini Kit (Qiagen,
Valencia, CA).

TaqMan reverse transcription reagents and gene expression assays

(Applied Biosystems, Foster City, CA) were used to reverse transcribe and to analyze the
expression of the following genes: F4/80, CD68, CD11c, CD206, MCP-1, TNFα, IL-10,
IL-6, and IL-1β. Potential reference genes (RPLP2, 18s, HMBS, TBP, B2M, H2AFV, and
HPRT) were analyzed for stability using Qbase+ software (Biogazelle, Belgium) for each
tissue analyzed. The optimal number of reference genes were determined by Qbase+ and
the geometric mean of these genes was used as the normalization factor for each analysis:
epididymal adipose tissue (HMBS, TBP, B2M, and H2AFV), peri-renal adipose tissue
(HMBS and HPRT), and liver (TBS and B2M) [119]. Gene expression quantification was
calculated using the ΔΔCT method and Qbase+ software.
Western Blotting: Briefly, epididymal and peri-renal adipose tissue, as well as a
portion of the liver was homogenized in Mueller Buffer containing a cocktail protease
inhibitor (Sigma Aldrich, St. Louis, MO) [70].

Total protein concentrations were

determined by the Bradford method. Equal amounts of crude protein homogenates were
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fractioned on hand-casted 12% SDS-polyacrylamide gel and electrophoretically
transferred to a PVDF membrane using a Genie Blotter (IDEA Scientific, Minneapolis,
MN). Membranes were stained with a Ponceau S solution in order to verify equal protein
loading and transfer efficiency. Subsequently, membranes were blocked for 1 hour in 5%
milk in Tris-buffered saline, 0.1% Tween-20 (TBST). The Ly6G primary antibody
(Abcam, Cambridge, UK) was diluted 1:1,000 in a 5% milk-TBST overnight at 4ºC. An
anti-rat (Cell Signaling, Danvers, MA) IgG horseradish peroxidase conjugated secondary
antibody was diluted 1:2000 in 5% milk-TBST and incubated for 1 hour at room
temperature.

An enhanced chemiluminescent substrate for detection of horseradish

peroxidase (Thermo Scientific, Watham, MA) was used to visualize the antibody-antigen
interaction. Autoradiography films were scanned and blots were quantified using scientific
imaging software (Image J). Due to tissue limitations, only the peri-renal fat from HFDfed animals was analyzed for Ly6G content. After completion of the western blot, all
membranes were stained with Amido black [49, 109, 116], and the densitometry of each
lane was calculated using Quantity One Software (Biorad, Hercules, CA) allowing for total
protein normalization. This method of normalization has been shown to be more accurate
than typically used loading controls [71].
Plasma Cytokines: Plasma collected at sacrifice was analyzed for circulating IL-6
and MCP-1 (LEGEND MAX ELISA kits, Biolegend, San Diego, CA). Due to limitations
in the amount of plasma only the plasma of the HFD-treated groups was analyzed for MCP1 concentration.
Statistical Analysis: Data were analyzed using commercially available statistical
software: Prism 6 (GraphPad Software, La Jolla, CA)) and SigmaStat (Systat Software,
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San Jose, CA). A two-way ANOVA followed by a Newman-Keuls post-hoc analysis was
used to determine differences between diet (HFD vs. LFD) and treatment (CLD vs. PBS).
For body weight analysis a two-way (time x group) repeated measures ANOVA was used
followed by a Newman-Keuls post-hoc test. A two-way (time x group) repeated measures
ANOVA followed by a Newman-Keuls post-hoc test was also used for ITT analysis in
order to determine differences in blood glucose levels from baseline (0 minutes) over the
duration of the test. A Student’s T-Test (two-tailed) was used for western blot analysis of
Ly6G, epididymal adipose tissue hydroxyproline content, and plasma MCP-1
concentrations to compare treatment (CLD vs. PBS) within diet. Statistical analysis of
energy intake was not assessed given the small sample size (n=3/group). Any statistical
test that did not pass the equal-variance test (Bartlett’s test for equal variances) was log
transformed and then re-analyzed. Data are presented as the mean ± SEMs and the level
of significance was set at p<0.05.

3.4 RESULTS
16 weeks of HFD consumption leads to an obese phenotype
Prior to CLD or PBS treatment, mice were fed a 40% HFD or a LFD for 16 weeks.
An obese phenotype was successfully achieved as the HFD-fed mice gained significantly
more body weight, fat mass, and displayed a significantly greater body fat % (Figure 3.1AB) compared to LFD fed mice (p<0.05). HFD-fed mice also displayed elevated fasting
blood glucose, insulin, GTT AUC, and impaired insulin sensitivity (Figures 3.1C, 1D, 1E,
and 1G, respectively), demonstrating a dysfunctional metabolic phenotype (p<0.05).
CLD treatment reduces body weight by eliciting changes in energy intake
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After 16 weeks of HFD or LFD consumption, mice were administered either PBS
or CLD-encapsulated liposomes for a 4-week period. The PBS-treated groups were pairfed the same amount of food as their CLD-treated counterparts. All CLD-treated groups
displayed a decrease in body weight starting one week after CLD treatment (Figure 3.2A)
which was accompanied by a decrease in energy intake (Figure 3.2B) suggesting that CLD
treatment induced a reduction in appetite. There was a main effect of the HFD-treatment
to increase lean mass, fat mass, and body fat% relative to the LFD-fed mice (Figure 3.2C)
(p<0.05). Pair feeding was successful in matching the body weight, fat mass and lean mass
in the PBS and CLD treatment groups. However, within the LFD groups, CLD treatment
significantly reduced body fat% (Figure 3.2C) (p<0.05). With respect to intra-peritoneal
fat pads, HFD increased all fat pad weights (epididymal, mesentery, and peri-renal) relative
to the LFD-fed mice (Figure 3.2D) (p<0.05). Interestingly, within the HFD-treated mice,
CLD-treated mice exhibited an increase in epididymal, but not peri-renal or mesenteric, fat
pad weight. Consequently, the sum of all three fat pads was also increased (Figure 3.2D)
(p<0.05). We found this surprising, and in order to potentially explain this discrepancy,
we examined a marker of extracellular matrix (Collagen) accumulation, hydroxyproline
content, in epididymal adipose tissue (HFD groups only).

However, no significant

difference was found in hydroxyproline content (data not shown) between these groups,
suggesting that some other mechanisms are responsible for the expansion of epididymal
fat pad weight between the HFD groups.
CLD-liposome treatment does not reduce epididymal adipose tissue macrophage
populations in a HFD setting, yet results in an exacerbated cytokine profile, and significant
increases in circulating and infiltrating neutrophils

43

We initially examined epididymal adipose tissue to assess the effectiveness of CLD
treatment to deplete macrophages as the epididymal fat pad has been shown to develop
signs of inflammation and insulin resistance prior to other intraperitoneal fat pads [120].
Interestingly, while as expected, the HFD increased adipose tissue macrophage markers,
no significant difference was found with respect to gene expression of overall macrophage
markers, F4/80 and CD68, or M1 (CD11c) and M2 (CD206) macrophage markers between
the HFD groups (Figure 3.3A). This lack of difference in macrophage populations was
substantiated when we performed immunofluorescence staining in the epididymal fat pad
(Figure 3.3B). However, within the LFD groups, CLD treatment significantly decreased
F4/80 (-58%), CD68 (-52%), and CD206 (-72%) gene expression, but not CD11c mRNA
expression (Figure 3.3A) (p<0.05).
We then proceeded to examine the gene expression of various inflammatory
cytokines in the epididymal fat pad (Figure 3.4A) (p<0.05). As expected, HFD treatment
significantly increased the gene expression of the monocyte chemoattractant, MCP-1, the
pro-inflammatory cytokine, TNF-α, as well as the anti-inflammatory cytokine, IL-10,
relative to the LFD groups (p<0.05). However, within the HFD groups, CLD treatment
further elevated gene expression of MCP-1 and IL-10 (p<0.05). An additional interest was
the finding that CLD treatment, independent of diet, resulted in substantial increases in
mRNA expression of the pro-inflammatory cytokines, IL-6 and IL-1β (p<0.05). In fact,
IL-1β mRNA induction was further augmented in the CLD LFD group relative to the CLD
HFD group, whereas its expression was downregulated in the HFD PBS group relative to
the LFD PBS group (p<0.05).
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Based on these findings, we performed H&E staining to histologically assess the
epididymal fat pads (Figure 3.4B).

We found clear evidence of infiltrating

polymorphonuclear cells (PMCs) in the CLD-treated groups relative to the PBS-treated
groups. Additionally, in whole blood collected at sacrifice, we found significant increases
in circulating neutrophils in the CLD-treated groups (Figure 3.5A). This finding led us to
believe that the tissue PMCs we examined histologically, were neutrophils. As such, we
performed a western blot for Ly6G, a neutrophil marker, and found significant increases in
Ly6G in the CLD-treated groups relative to their PBS controls (Figure 3.5B) (p<0.05).
This discovery was corroborated with immunohistochemistry staining of Ly6G (Figure
3.5C).
Macrophage populations are significantly diminished in peri-renal adipose tissue, yet a
pro-inflammatory environment including neutrophil infiltration is evident
Because we did not find any significant decreases in macrophage populations in the
epididymal fat pad, we decided to assess the peri-renal fat pad with respect to macrophage
infiltration. Contrary to the finding in the epididymal fat pad, CLD treatment significantly
decreased F4/80 (-30%), CD68 (-35%), CD11c (-40%), and CD206 (-42%) in the CLD
HFD group relative to the PBS HFD group (Figure 3.6A) (p<0.05), which was corroborated
with immunofluorescent staining for F4/80 (Figure 3.6B). In the LFD groups, a similar
pattern was found as CLD treatment reduced mRNA content of F4/80 (-43%), CD68 (35%), and CD206 (-47%) (Figure 3.6A) (p<0.05). However, similar to the epididymal
adipose tissue, CLD treatment did not influence CD11c gene expression.
Since we found reduced macrophage populations in the CLD-treated groups, we
moved on to explore the gene expression of several pro-inflammatory cytokines (TNF-α,
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MCP-1, IL-1β, and IL-6). As expected, there was a HFD effect to increase TNF-α and
MCP-1 expression (Figure 3.7A) (p<0.05). On the other hand, IL-6, similar to the finding
in epididymal adipose tissue, was downregulated as a result of HFD consumption (p<0.05).
In a HFD setting, CLD treatment significantly decreased TNF-α gene expression (-31%),
which corresponded with the similar decrease (-30%) in F4/80 mRNA (Figure 3.7A)
(p<0.05). However, analogous to what was observed in the epididymal adipose tissue,
MCP-1, IL-1β, and IL-6 were all increased as a result of CLD treatment among the HFD
groups (Figure 3.7A) (p<0.05). A similar finding was observed with CLD treatment in a
LFD setting as both IL-1β and IL-6 expression were significantly increased (p<0.05). This
outcome, paired with no change in MCP-1 gene expression, paralleled what was observed
in epididymal adipose tissue.
We followed up the qRT-PCR analysis with a histological assessment of the perirenal fat pad and, similar to what was observed in the epididymal fat pad, discovered an
abundance of infiltrating PMCs surrounding adipocytes.

Immunohistochemistry

confirmed that these cells were Ly6G positive cells (Figure 3.7B). A western blot analysis
of Ly6G verified that Ly6G content was greater in the CLD-treated mice (Figure 3.7C)
(p<0.05).
CLD treatment does not regress early-stage NAFLD development
HFD treatment resulted in early-stage NAFLD development as characterized by
hepatomegaly (Figure 3.8A), hepatic steatosis (Figure 3.8B & 8D), and elevated plasma
ALT activity (Figure 3.8C) (p<0.05).

However, the disease had not progressed to

steatohepatitis as the HFD PBS group, although it did display an increase in F4/80
expression relative to the LFD PBS group (Figure 3.8E & 8F) (p<0.05), did not
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histologically present significant evidence of immune cell infiltration. Moreover, nor were
there any significant increases in any of the pro-inflammatory cytokines measured,
including MCP-1, TNF-α, IL-6, and IL-1β (Figure 3.8G). In fact, there was a main effect
for HFD consumption to decrease MCP-1 gene expression, and the HFD PBS group
displayed less TNF-α gene expression relative to the LFD PBS group (p<0.05).
Regardless of the lack of HFD-induced hepatic inflammation, CLD treatment
significantly reduced gene expression of F4/80 (-59%) in a HFD setting (Figure 3.8E).
This was substantiated by F4/80 staining (Figure 3.8F) and occurred independent of any
changes to liver weight or hepatic lipid accumulation. Surprisingly, this decrease in F4/80
did not impact gene expression of MCP-1 or TNF-α (Figure 3.8G). Additionally, CLD
treatment in a LFD setting did not significantly reduce macrophages as substantiated by
F4/80 gene expression and immunohistochemistry (Figures 8E & 8F, respectively), yet
there was a main effect for CLD treatment to decrease TNF-α and IL-1β (Figure 3.8G)
(p<0.05). Despite these reductions in TNF-α and IL-1β, CLD treatment, independent of
diet, resulted in higher IL-6 gene expression (Figure 3.8G) (p<0.05).
Macrophage depletion elicits significant increases in circulating IL-6 and MCP-1
Because we found a main effect of CLD treatment to increase gene expression of
IL-6 in all tissues analyzed and an interaction for CLD treatment to increase epididymal
and peri-renal MCP-1 gene expression among the HFD groups, we examined circulating
IL-6 and MCP-1 levels (Figure 3.9). Consistent with the gene expression, CLD treatment,
irrespective of diet, induced significant increases in the plasma IL-6 concentration (Figure
3.9A) (p<0.05). Additionally, CLD-treated HFD mice displayed >2-fold increases in
circulating MCP-1 relative to HFD PBS mice (Figure 3.9B) (p<0.05).
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Macrophage depletion does not rescue impaired glucose metabolism or insulin resistance
and exacerbates adipose tissue insulin action
CLD treatment had no effect at improving glucose metabolism or insulin resistance
as fasting blood glucose (Figure 3.10A), fasting insulin (Figure 3.10B), and GTT AUC
(Figure 3.10C), were not reduced with CLD treatment in either the LFD or HFD groups.
Similarly, insulin’s ability to decrease blood glucose levels (Figure 3.10D) was not
enhanced with CLD treatment in either the LFD or HFD setting. With respect to FFA
metabolism, basal serum FFAs were significantly increased in the LFD PBS group
compared to all other groups (Figure 3.10E) (p<0.05). Thirty minutes after exogenous
insulin administration there was a main effect of diet (p<0.05) for the LFD-fed mice to
exhibit significantly lower serum FFAs than HFD-fed mice (Figure 3.10F).

When

examining the absolute change of serum FFAs over the thirty-minute period, there was a
main effect of CLD treatment to impair the decrease in serum FFAs compared to PBS
treatment. Among the groups, the LFD PBS group displayed the greatest drop in serum
FFAs compared to all other groups (Figure 3.10G) (p<0.05). LFD CLD mice exhibited a
more significant drop in serum FFAs than the HFD CLD mice (p<0.05), but not when
compared to the HFD PBS mice. Although not statistically significant, there was a trend
(p=0.08) for the HFD PBS mice to decrease serum FFAs more so than the HFD CLD group.
CLD treatment results in anemia
It is well established that macrophages play a central role in heme-iron metabolism
[121-123]. Therefore, we analyzed whole blood to see if CLD treatment impacted
hemoglobin levels. Data from the hematology analysis showed that CLD treatment,
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independent of diet, decreased absolute hemoglobin levels and the hematocrit (Table 3.2)
(p<0.05).

3.5 DISCUSSION
Due to the prominent role macrophages play in obesity-associated inflammation,
they have become the target for therapies aimed at mitigating the chronic inflammatory
environment and impaired metabolic processes. As others have reported, adipose tissue
macrophages (peri-renal) were successfully reduced with CLD-liposome treatment [99,
100, 114, 124]. However, relative to weight-matched control animals, CLD treatment did
not rescue HFD-induced impaired glucose metabolism.

Moreover, CLD treatment,

irrespective of diet, increased circulating and adipose tissue infiltrating neutrophils.
Additionally, we found that CLD treatment resulted in reduced energy intake and
significant body weight loss.
Interestingly, others who have utilized CLD liposomes to decrease obesity-induced
adipose tissue macrophage infiltration have not reported similar findings of neutrophilia,
an inability to rescue impaired metabolism, and reduced energy intake [99, 100, 104, 124].
However, our results are consistent with those of Lee et. al., who found that macrophage
depletion utilizing a Lysozyme M promoter-directed CRE (LysMCre) diphtheria toxin
model resulted in significant neutrophil infiltration, decreased energy intake, and reduced
body weight in both HFD and standard-chow-fed mice [101]. Similarly, Gordy et. al.
developed a LysMCre floxed FLICE-like inhibitory protein (LysMCre c-FLIPf/f) mouse
model which results in mice lacking splenic marginal zone, bone marrow, and
thioglycolate-elicited peritoneal macrophages and found that neutrophilia is secondary to
macrophage depletion and macrophages regulate neutrophil homeostasis [102]. Although
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energy intake was not measured in the study by Gordy et. al., it was discovered that these
mice exhibit a decreased body weight. Similar results of neutrophilia and a loss of body
weight were reported by Wu et. al. when conditional macrophage depletion via the use of
a transgenic mouse model was used to study the impact of macrophages on osteoarthritis
in obesity [103]. The results of Lee et. al., Gordy et. al., and Wu et. al. and the mouse
models utilized in their studies provide support that our findings are a direct result of
macrophage depletion and not of CLD liposome treatment alone.
It was surprising that we did not find significant decreases in macrophage
populations in the epididymal adipose tissue of the HFD CLD group. It was our initial
hypothesis that epididymal adipose tissue would be the most sensitive to CLD treatment
given the route of liposome administration and that the epididymal fat pad exhibits
exacerbated inflammation and impaired insulin action at an earlier time point than other
intra-peritoneal fat pads [120].

However, the fact that CLD treatment significantly

depleted epididymal and peri-renal adipose tissue macrophages in a LFD setting and
resulted in significant peri-renal adipose tissue macrophage depletion in a HFD setting
leads us to believe that perhaps epididymal adipose macrophages are more sensitive to the
pair feeding. Prior work demonstrated that restricting food intake in obese animals reverses
macrophage accumulation in peri-gonadal adipose tissue [125]. As we are comparing the
CLD treatment to pair-fed animals who lost weight, it is possible that CLD could not reduce
macrophage populations beyond that seen with caloric restriction. Alternatively, the
inability to detect a difference in epididymal adipose tissue macrophage populations may
be due to the immune system’s ability to compensate for the effects of CLD treatment in
order to recruit more monocytes to the inflamed area resulting in a repopulation of
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macrophages.

This is supported by the significant increase in epididymal mRNA

expression of the potent monocyte chemokine, MCP-1 (as has been previously shown with
acute IP CLD liposome treatment [114]), a higher concentration of circulating MCP-1 as
well as tissue neutrophilia in the HFD CLD group. However, a time-course study with
CLD treatment would be necessary to confirm this.
It is important to consider that dendritic cells, another phagocytic immune cell, are
also known to be affected by CLD-liposome treatment [126]. Thus, the neutrophil
infiltration makes physiological sense as they are the only primary professional phagocytic
cell remaining after macrophage and dendritic cell depletion. Neutrophil infiltration into
the adipose tissue serves two probable functions: 1) remove dead immune cells affected by
CLD treatment, and 2) adopt the role of macrophages by cleaning up dead adipocytes. This
is supported by the observation of Ly6G positive cells surrounding adipocytes in the CLDtreated mice. Additionally, it is likely that the increased expression of adipose tissue IL-6
and IL-1β as well as the circulating IL-6 concentration originates from these infiltrating
neutrophils as the HFD PBS treatment did not induce significant increases in these
cytokines relative to the LFD PBS group. Furthermore, both Lee et. al. and Gordy et. al.
found that macrophage-depletion-induced neutrophilia resulted in significant increases in
circulating plasma cytokines, including IL-6 [101, 102] and IL-1β [102]. However, we
cannot rule out the possibility that other immune cells, such as T-Cells, or adipocytes could
be producing these cytokines.
There is a clear discrepancy between the results of our study and the studies of
others who have shown macrophage depletion to improve metabolic processes through the
use of CLD treatment [99, 100, 104, 124, 127]. In particular, our results are in direct
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contradiction of Lee et. al. who have suggested that “long-term” obesity-associated insulin
resistance, as would be induced after 16 weeks of HFD consumption, is largely mediated
by macrophage-induced pro-inflammatory actions [124]. These discrepancies may be
explained by many factors including, but not limited to, the type of HFD utilized, the mode
of CLD administration (IP vs. IV), as well as the dose, timing, and duration of CLD
treatment. For instance, the mode of CLD liposome administration can have a significant
effect on the tissue specificity of macrophage depletion. Lanthier et. al. showed that IV
administration of CLD liposomes selectively depletes Kupffer cells (liver macrophages),
whereas IP administration is more advantageous for adipose tissue macrophage depletion
[114]. With this being said, the majority of previous studies employing CLD liposomes
to deplete adipose tissue macrophages have utilized IP administration [99, 100, 104, 124,
127] as was used in our experiment. However, the CLD dose (≈0.03 mg/g body weight)
utilized in our study was significantly less than what others have used (≈0.1 mg/g body
weight) [99, 100, 124]. Furthermore, the degree to which the duration of CLD liposome
treatment impacts the effectiveness of macrophage depletion and the resulting impact on
metabolic function is conflicting. Studies that have employed IP administration of CLD
liposomes for a relatively short period (1-2 weeks), such as Feng et. al. [100], Choe et. al.
[127] (2 treatments/week x 1 week) and Lee et. al. (“5 injections every 3 days for 14 days”
(provided in supplementary data of their paper)) [124] have shown effective macrophage
depletion and beneficial effects on metabolic outcomes. The duration (2 treatments/week
x 4 weeks) of CLD liposome administration in our study was significantly longer than these
previous studies and may be largely responsible for the discrepancy in outcomes between
studies. However, Bu et. al. used CLD liposome treatment for a significantly longer
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duration (2 treatments/week x 9 weeks) than what was used in our study yet showed
beneficial effects on adiposity and metabolism [99].
A potential confounding factor for the majority of the previous studies utilizing IP
CLD-liposome treatment, however, is the failure to examine/report energy intake or body
weight changes with CLD treatment [100, 124, 127]. Moreover, those studies that did
report significant changes in body weight did not report energy intake as exemplified in a
recent publication by Kumar et. al. who used a similar dose of CLD liposome as the dose
utilized in our study (≈0.03 mg/g body weight administered weekly for 4 weeks) and found
that CLD liposome treatment significantly depleted adipose tissue macrophages, improved
metabolic outcomes, and dramatically reduced adiposity by >50% [104]. In the publication
by Bu et. al., food intake was reported, however, the authors did not specify the number of
mice housed/cage, the means by which energy intake was calculated if multiple mice were
housed/cage, and the statistical analysis utilized to assess a potential difference in energy
intake [99]. Thus, in these previous studies any potential benefits with respect to decreases
in adiposity, inflammation, insulin resistance, and hepatic steatosis as a consequence of
macrophage depletion, may in reality simply be a secondary effect resulting from decreased
energy intake.
Although it was beyond the scope of our investigation, it is likely that the reduced
energy intake and consequential body weight loss resulting from CLD-liposome treatment
is due to neutrophilia, an exacerbated circulating pro-inflammatory environment, and brain
inflammation. However, it cannot be ruled out that liposome treatment, alone, may have
reduced food intake as previously discussed [128]. With this being said, in our previous
publication we did not find any effect of PBS-liposome treatment to impact body weight
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or food intake [49]. Moreover, the concept that reduced energy intake is due to CLDliposome treatment and subsequent macrophage depletion and not liposome treatment, in
general, is supported by the findings of Lee et. al. who showed that macrophage-depleted
mice present hypothalamic inflammation and reduced energy intake [101]. It has also been
shown that IL-1β plays a key role in regulating this effect as Gordy et. al. found that
administration of IL-1Ra to macrophage-deficient mice rescued the decreased body weight
[102]. Consistent with this, both in the present investigation and in that of Lee et. al.,
decreased energy intake was observed with macrophage depletion as was increases in
adipose tissue IL-1β gene expression, which Lee et. al. also found to be elevated in the
hypothalamus [101].
Others have shown that hepatic resident macrophage (Kupffer cells) activation has
been shown to impair insulin signaling in the early stages of HFD consumption [129]. As
such, we assessed whether or not CLD treatment reduced Kupffer cell accumulation in our
model. Although there was evidence of NAFLD, as assessed by hepatic steatosis, elevated
plasma ALT activity, and an increased macrophage content, there was no effect of the HFD
to induce robust hepatitis as substantiated by no significant increases in various
inflammatory markers (MCP-1, TNF-α, IL-6, and IL-1β). It is likely that a longer feeding
period would be necessary to develop a more advanced NAFLD phenotype. Nonetheless,
CLD treatment significantly decreased macrophages (F4/80) in a HFD setting. However,
glucose metabolism was not improved. Lanthier et. al. found similar results and concluded
that Kupffer cell depletion does not provide a therapeutic effect on detrimental metabolic
changes induced by a HFD [114]. Thus, our results provide further support that ectopic
lipid accumulation resulting from a positive energy balance may be a more important
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instigator if impaired metabolic processes than inflammation as has been previously shown
[130].
A limitation of our study is that CLD treatment is a non-specific means of depleting
macrophage populations. It is well established that different macrophage subsets exist, that
are generally categorized into two extreme phenotypes – pro-inflammatory and antiinflammatory.

Although this dichotomy does not fully reflect the heterogeneity of

macrophage populations, it is still a widely used distinguishing characteristic. Therapies
specifically targeting individual macrophage phenotypes or specific tissue macrophage
may be more effective than general systemic macrophage depletion [131]. However, the
establishment of such models and tissue specificity is still in its infancy.
It is important to note that CLD-treated groups displayed symptoms of anemia.
Macrophages play an essential role in heme and iron metabolism [121-123]. Iron can also
modulate glucose homeostasis and adipose tissue function [132]. Thus, it is imperative
that a complete blood count be part of a routine assessment when interventions aimed at
modulating macrophage populations are utilized. This is especially true in an obese setting
as obesity is emerging as a risk factor for iron deficiency [133]. It is also evident from our
results that severe macrophage depletion and subsequent compensatory immune responses
can be lethal in certain conditions. This is consistent with other macrophage-depletion
models [134, 135]. We hypothesize that the larger degree of toxicity observed in the LFD
CLD group is the result of an immunocompromised state from severe macrophage
depletion not reached in the HFD CLD group. This is likely the case given that adipose
tissue macrophage populations of the LFD group would have been significantly less than
the HFD-fed mice after 16 weeks of dietary treatment, as we have previously shown [67,
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109]. Future assessments to evaluate potential toxicity of macrophage depletion - even in
the short-term - are necessary prior to any clinical interventions aimed at macrophage
diminution.
In conclusion, our study shows that when controlling for energy intake, depleting
macrophages using CLD in an obese setting is not an effective therapy for rescuing
metabolic dysfunction and may increase the risk for anemia, neutrophilia, and exacerbated
adipose tissue inflammation. Thus, the utilization of pro-longed repeated IP CLD liposome
treatment to deplete macrophages does not seem to be a viable option as a potential clinical
therapy. Future studies are necessary to better understand the role that the timing, tissuespecificity, and phenotype of macrophage depletion has on obesity outcomes.
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3.6 FIGURES & LEGENDS
Table 3.1. Primary and secondary antibodies as well as conditions used for
immunofluorescence and immunohistochemistry.
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Figure 3.1. Body composition and metabolic data after 16 weeks of dietary treatment prior
to start of liposome treatment. Mice were fed a high-fat diet (HFD) or (LFD) for 16 weeks.
A) Mouse body weight, B) body composition, C) fasting (5 hour) blood glucose levels, D)
fasting (5 hour) plasma insulin levels, E) intraperitoneal (IP) glucose tolerance test (GTT)
and corresponding area under the curve (AUC), F) IP insulin tolerance test (ITT) following
a 5-hour fast. Values are means ± SE; n=9-15 mice per group. * and bar graphs not sharing
a common letter are significantly different from one another (p<0.05). %, $, #, ^ represent
statistically significant differences (p<0.05) in blood glucose levels from baseline (0
minutes) for the LFD PBS, LFD CLD, HFD PBS, and HFD CLD groups, respectively.
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Figure 3.2. Body morphology following dietary and liposome treatment. A) Mouse body
weight, B) energy (kcal) intake throughout the experimental protocol, C) terminal body
composition analysis as assessed by DEXA, and D) intra-peritoneal adipose tissue depot
weights (epididymal, peri-renal, mesentery) and total intra-peritoneal fat weight measured
at sacrifice. Values are means ± SE; n=9-15 mice per group. *Signifies significant
difference from start of liposome treatment at 16 weeks. Bar graphs not sharing a common
letter are significantly different from one another (p<0.05).
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Figure 3.3. Four weeks of CLD treatment depletes epididymal adipose tissue macrophages
in a low-fat diet (LFD) setting, but not under high-fat diet (HFD) conditions. (A)
Epididymal adipose tissue mRNA expression of macrophage markers (F4/80, CD68,
CD11c, and CD206) normalized to the most stable internal reference genes calculated
using Qbase+ software, and B) representative immunofluorescent images (40X) of DAPI
and F4/80 in epididymal adipose tissue of HFD-treated mice. Values are means ± SE; n=915 mice per group. Bar graphs not sharing a common letter are significantly different from
one another (p<0.05).
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Figure 3.4. Despite not affecting epididymal adipose tissue macrophage populations in a
HFD setting, CLD treatment augments epididymal adipose tissue inflammation and
polymorphonuclear cell (PMC) infiltration. A) Epididymal adipose tissue mRNA
expression of inflammatory mediators (MCP-1, TNF-α, IL-10, IL-6, and IL-1β)
normalized to the geometric mean of the most stable internal reference genes calculated
using Qbase+ software, and B) representative images (20X and 100X) of H&E stained
epididymal adipose tissue sections showing increased (PMC) infiltration in the CLDtreated groups. Values are means ± SE; n=9-15 mice per group. Bar graphs not sharing a
common letter are significantly different from one another (p<0.05).
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Figure 3.5.
CLD treatment increases circulating and epididymal adipose tissue
neutrophils. A) Circulating neutrophils determined in whole blood by a VetScan HM5, B)
western blot analysis of Ly6G (neutrophil marker) in epididymal adipose tissue normalized
to total protein stain (amido black), and C) two representative images of
immunohistochemistry staining (100x) of Ly6G in epididymal adipose tissue. Values are
means ± SE; n=9-15 mice per group. Bar graphs not sharing a common letter and the *
represent a statistically significant difference between groups (p<0.05).
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Figure 3.6. Four weeks of CLD treatment depletes macrophages in the peri-renal fat pad.
A) Peri-renal adipose tissue mRNA expression of macrophage markers (F4/80, CD68,
CD11c, and CD206) normalized to the geometric mean of the most stable internal reference
genes using QBase+ software, and B) representative immunofluorescent images (40X) of
DAPI and F4/80 in peri-renal adipose tissue of HFD-treated mice. Values are means ± SE;
n=9-15 mice per group. Bar graphs not sharing a common letter are significantly different
from one another (p<0.05).
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Figure 3.7. An increase in peri-renal adipose tissue inflammation is paired with an increase
in infiltrating neutrophils. A) Peri-renal adipose tissue mRNA expression of inflammatory
mediators (TNF-α, MCP-1, IL-1β, and IL-6) normalized to the geometric mean of the most
stable internal reference genes using QBase+ software, B) two representative images of
immunohistochemistry staining (100x) of Ly6G in peri-renal adipose tissue of HFD-treated
groups, C) western blot analysis of Ly6G in epididymal adipose tissue normalized to total
protein stain (amido black). Values are means ± SE; n=9-15 mice per group. Bar graphs
not sharing a common letter and the * represent a statistically significant difference
between groups (p<0.05).
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Figure 3.8. CLD treatment has no affect at regressing early-stage NAFLD development.
A) Liver weight following sacrifice, B) hepatic lipid accumulation, C) plasma Alanine
Transaminase (ALT) Activity, D) representative hepatic H&E (20x) images, E) hepatic
gene expression of F4/80, F) representative F4/80 staining (60x, arrows indicate examples
of positive staining), and G) mRNA expression of hepatic inflammatory mediators (MCP1, TNF-α, IL-6, and IL-1β) normalized to the geometric mean of the most stable internal
reference genes using QBase+ software. Values are means ± SE; n=9-15 mice per group.
Bar graphs not sharing a common letter are significantly different from one another
(p<0.05). %, $, #, ^ represent statistically significant differences (p<0.05) in blood glucose
levels from baseline (0 minutes) for the LFD PBS, LFD CLD, HFD PBS, and HFD CLD
groups, respectively.
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Figure 3.9. CLD treatment significantly increases circulating pro-inflammatory cytokine
concentrations. After 20 weeks of diet/4 weeks of clodronate liposome treatment, plasma
was assessed for circulating pro-inflammatory cytokines: A) IL-6 and (B) MCP-1. Due to
limitations in the amount of plasma, only the plasma of HFD-treated groups was assessed
for the concentration of circulating MCP-1. Values are means ± SE; n=7-14 mice per
group. Bar graphs not sharing a common letter are significantly different from one another
(p<0.05).
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Figure 3.10. CLD treatment does not rescue impaired glucose metabolism or insulin
resistance and exacerbates adipose tissue insulin action. After 20 weeks of diet/4 weeks of
clodronate liposome treatment, metabolic outcomes were assessed: A) fasting (5 hour)
blood glucose levels, B) fasting (5 hour) plasma insulin levels, C) intraperitoneal (IP)
glucose tolerance test (GTT) and corresponding area under the curve (AUC), D) IP insulin
tolerance test (ITT) following a 5-hour fast, E) serum free-fatty-acid (FFA) concentration
following a 5-hour fast measured at the 0 and F) 30-minute time point of the ITT, and G)
change in serum FFAs from 0-30 minutes of the ITT. Values are means ± SE; n=9-15 mice
per group. Bar graphs not sharing a common letter are significantly different from one
another (p<0.05).
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Table 3.2. CLD treatment results in anemia. Whole blood collected at sacrifice (4 weeks
after liposome treatment) was assessed for mean corpuscular hemoglobin concentration, as
well as hemoglobin, and % hematocrit. Values are means ± SE; n=9-15 mice per group.
Groups not sharing a common letter differ significantly from one another (p<0.05).
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CHAPTER 4

SEX DISPARITIES IN OBESITY-ENHANCED COLON CANCER:
DETRIMENT OF ADIPOSITY AND MACROPHAGE ASSOCIATED
INFLAMMATION3

3

Bader JE, Carson MS, Enos RT, Velázquez KT, Sougiannis AT, Singh UP, Becker WJ,
Nagarkatti M, Robinson CM, Murphy EA. Sex Disparities in obesity-enhanced Colon
Cancer: Detriment of Fat Distribution and Macrophage Associated Inflammation.
Manuscript in Preparation
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4.1 ABSTRACT
Given the high prevalence of colorectal cancer (CRC) in the United States and the
increased risk for of CRC in the obese population, it is important to understand the
underlying mechanisms that link obesity to CRC. Currently, there is increased incidence
within obese males compared to obese females, and evidence suggests that female sex
hormones may offer certain protection against obesity enhanced CRC. In this study, MC38
murine colon adenocarcinoma cells were injected subcutaneously (2x105cells/100L) in
obese mice with associated metabolic dysfunctions following 20 weeks of high fat diet
feeding to better elucidate the mechanisms behind tumor growth in an obese state. This
was performed in C57BL/6J males, females and females that underwent ovariectomy
(OVX), in order to further examine the influence of female sex hormones in this obesity
enhanced CRC model. Our results indicate that enhanced tumor growth occurs following
diet induced obesity and insulin resistance. Among mice fed a high fat diet, OVX mice
exhibited the most significant tumor growth compared to males and females (p=0.036 and
0.001 respectively).

Furthermore, OVX mice presented with increased CD206 and

decreased CD11c gene expression of macrophages isolated from tumors compared to those
of female mice. This increase in tumor growth and altered tumor associated macrophage
phenotype were attributed to increased subcutaneous adipose tissue and adipose tissue
inflammation present in the high fat diet OVX group following 20 weeks of diet feeding.
This study provides evidence suggesting adiposity and macrophage associated adipose
inflammation as potential mechanisms underlying female derived protection against
obesity-associated CRC.
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4.2 INTRODUCTION
It has been established that there is a positive relationship between obesity and
CRC. Obese men have a higher risk of CRC compared with normal weight men, but this
association is much weaker in women [136]. On the other hand, postmenopausal women
have an increased risk of obesity, insulin resistance and consequently have an increased
incidence of CRC compared to premenopausal women [137, 138]. Interestingly, hormone
replacement therapy (HRT), has been shown to reduce the risk of CRC in postmenopausal
women although some studies have shown inconclusive effects [139].
Epidemiological studies have shown that distribution of fat increases susceptibility
to inflammation induced insulin resistance, which enhances CRC risk. Although females
have a larger proportion of body fat mass compared to males, the distribution of adipose
tissue in males is primarily abdominal which is more closely linked to worsened insulin
sensitivity [140]. Visceral adipose tissue, as opposed to subcutaneous or total body fat is
presumed as the particular location for which these metabolic risk factors for CRC arise
[141]. Furthermore, visceral adiposity correlates with increased circulating proinflammatory adipokines, which can promote cellular proliferation, and angiogenesis
[142]. This evidence suggests that adiposity, specifically location of adiposity, is strongly
associated with obesity induced insulin resistance and CRC.
This obesity associated inflammation is strongly influenced by immune cell
populations, particularly macrophages present in the adipose tissue depots. Studies by our
laboratory (unpublished) show a sex-specific association of obesity with macrophage
phenotype.

This data indicates that male mice have a significant increase in pro-
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inflammatory M1 macrophages in response to high fat diet whereas minimal increases are
seen in female mice. The ovariectomy of female mice results in increased M1 macrophages
similar to males, which is reversed upon estrogen replacement. This suggests that a
combination of differential fat distribution and adipose tissue macrophage associated
inflammation between men, women, and postmenopausal women may provide a
mechanism for the differential incidence of CRC within those populations.
Additional evidence supports a potentially protective role of estrogen against
inflammation and obesity associated insulin resistance [143]. However, current literature
does not provide a conclusive role for estrogen in CRC. Further, there are few studies that
have examined the role of estrogen in CRC in the settings of obesity. This is largely due
to the difficulties in choosing appropriate methods for either establishing obesity or
inducing CRC. Studies from our laboratory have shown that diet induced obesity increases
the mucin production within the colon in the chemically induced AOM/DSS colon cancer
model and thus affect the effectiveness of DSS induced inflammation to cause CRC [144].
Furthermore the transgenic ApcMin/+ mouse model for intestinal cancer is ineffective at
testing obesity enhanced CRC because the genetic mutation of APC gene is present and
expressed at birth. This results in development of intestinal polyps before obesity or
associated metabolic dysfunctions can be established [113]. Due to these limitations in
more commonly used CRC models, we utilized the subcutaneous MC38 tumor model,
which allowed us to establish an obese phenotype with associated metabolic dysfunction
prior to the initiation of cancer in order to better elucidate the mechanisms behind increased
colon cancer risk in an obese population.
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Given the high prevalence of CRC in the United States and the increased risk for
of CRC in the obese population, it is important to elucidate the mechanistic link between
obesity and CRC. In this study, we examined adiposity and macrophage associated
inflammation as potential mechanisms influencing sex disparities within colon derived
tumor growth following diet-induced obesity.
4.3 MATERIALS & METHODS
Animals: Male and female WT C57BL/6J mice were purchased from the Jackson
Laboratories (Bar Harbor, ME) and cared for at the Department of Laboratory Animal
Resources at the University of South Carolina. Mice (n=15/group) were housed 5 per cage,
maintained on a 12:12-h light-dark cycle in a low stress environment (22°C, 50% humidity,
low noise) and given water ad libitum. Principles of laboratory animal care were followed,
and the Institutional Animal Care and Usage Committee of the University of South
Carolina approved all experiments. At 9 weeks of age male mice underwent a sham surgery
and female mice underwent either a sham or ovariectomy (OVX) surgery. Briefly, mice
underwent anaesthesia maintained with 2% isoflurane and oxygen before a dorsal incision
was made to the skin then the muscle layers. Both uterine horns were tied with nonabsorbable suture 5-0 (cat # S-G518R13) and ovaries were removed. In case of the shamoperated mice, the ovaries were exteriorized and then placed back intact into the abdominal
cavity. The muscle wall was sutured with with 5-0 absorbable suture (cat # S-G518R13U) and wound clips were used to close skin incision. Buprenorphine was given as pain
reliever subcutaneously at a dose of 0.043 mg/kg. Wound clips were removed 1 week after
surgery and mice were allowed to recover for an additional week prior to initiation of diet
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feedings.

The experiment was performed over 3 independent blocks, with n=5

mice/group/block for a total of n=15/group.
Diets: At 11 weeks of age, mice (Male, Female and OVX) were randomly assigned to
either control purified AIN-76A low-fat diet (LFD) (3.77 kcal/g) or a purified HFD (40%
of total kcals from fat; 4.57 kcal/g) designed to mimic the standard American diet (BioServ,
Frenchtown, NJ, USA). We have used this diet in several of our previous studies [50, 67,
109-113]. Mice were initially provided the respective LFD or HFD for 20 weeks at which
time baseline body composition (DEXA) and metabolic tests were performed. Following
MC38 colon cancer cell injection (described below), mice continued their respective diets
(LFD or HFD) for another 3 weeks. Thus, in total, mice consumed the assigned diets for
23 weeks.
Body weights, body composition and metabolism: Body weight was monitored on a weekly
basis throughout the study. Body composition was assessed before cancer cell injection at
20 weeks of diet feeding. For this procedure, mice were placed under brief anesthesia
(isoflurane inhalation) and were assessed for lean mass, fat mass, body fat percentage and
bone mineral density via dual-energy X-ray absorptiometry (DEXA) (Lunar PIXImus,
Madison, WI). Metabolic parameters were assessed at 20 weeks of dietary treatment. After
a five-hour fasting, blood samples were collected from the tip of the tail. Blood glucose
concentrations were determined in whole blood using a glucometer (Bayer Contour,
Michawaka, IN). Collected blood was centrifuged at 4,000 rpm for 10 min at 4°C. Plasma
was aliquoted and stored at -80°C until analysis. Plasma insulin concentrations were
analyzed using a mouse insulin ELISA kit according to the manufacturer’s instructions
(Mercodia Inc., Winston Salem, NC). Insulin resistance was estimated by HOMA index
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according to the following formula: insulin resistance index = fasting insulin (μU/ml) x
fasting glucose (mmol/l)/22.5. For glucose tolerance tests (GTTs) and insulin tolerance
tests (ITTs), mice were fasted for 5 hours and glucose or insulin was administered (IP) at
a dose of 2 g/kg or 0.75 U/kg lean mass, respectively. Blood glucose concentrations (tail
sampling) were measured intermittently over a two-hour period (0, 15, 30, 60, 90, and 120
minutes) for GTTs and intermittently over a one-hour period (0, 15, 30, 45, and 60 minutes)
for ITTs using a glucometer (Bayer Contour, Michawaka, IN). Area under the curve
(AUC) was calculated using the trapezoidal rule.
Subcutaneous Tumor Model: MC38, murine colon adenocarcinoma cells (Kerafast), were
maintained in complete DMEM 4.5g/L glucose with 10% fetal bovine serum, 2mM
glutamine, and 1% penicillin/streptomycin. Cells were routinely passaged when 80%
confluence was reached under sterile conditions and maintained in a 37°C, 5% CO2
incubator. Prior to injection, cells (passage <20) were trypsinized, washed, counted with
a hemocytometer and resuspended at 2x106 cells/mL in phosphate buffered saline. Mice
were briefly anesthetized (isoflurane inhalation), and 100L of MC38 cell suspension
(2x105cells/100L/mouse) was injected subcutaneously using a 0.3mL 29G syringe into
the left dorsal lumbar region of each mouse. Viability of the cell suspension was confirmed
>95% using trypan blue staining before and after all injections were completed.
Tissue collection: After 23 weeks of dietary treatment (3 weeks after tumor injection), mice
were sacrificed via isoflurane inhalation for tissue collection. Whole blood taken from the
inferior vena cava was analyzed for hematology analysis using a VetScan Hm5 (Abaxis,
Union City, CA). The blood was spun at 4,000 RPM x 10 min and aliquoted plasma was
stored -80°C. Gonadal, mesentery, and peri-renal fat pads, as well as the liver and spleen
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were removed, weighed, and immediately snap-frozen in liquid nitrogen and stored at
−80°C until analysis. Subcutaneous tumors were removed, weighed and measured (length
and width) using calipers. Half of the tumor was placed in complete DMEM to be used for
cell sorting. The other half was snap frozen and stored at -80°C until analysis.
Flow Cytometry and Cell Sorting: Tumors were mechanically disrupted in PBS with 5%
FBS using the gentleMACS dissociate and tumor associated macrophages (TAMs) were
isolated using FACS as described [145]. Briefly tumor isolates underwent RBC lysis and
filtered through a 100M then 70M cell strainer prior to being stained with CD45-APC,
F4/80-PE, and CD11b-FITC (Biolegend, San Diego, CA) antibodies for 30 minutes.
Following compensation using unstained and single stained controls, tumor associated
macrophages were quantified by gating for CD45+ cells followed by F480 and CD11b
double positive gate. TAMs were sorted into a separate tube containing PBS with 5% FBS
and kept on ice until all samples were sorted. Data were acquired using a BD FACS Aria
II cell sorter and analyzed using DIVA software. Freshly sorted TAMs were spun at 2000
RPM x 5min, resuspended in trizol reagent and stored at -20⁰C until RNA isolation.
Quantitative real-time RT-PCR: RNA was isolated from fluorescent activated cell sorted
TAMs, and gonadal and subcutaneous adipose tissue depots using trizol reagent. TaqMan
reverse transcription reagents and gene expression assays (Applied Biosystems, Foster
City, CA) were used to reverse transcribe and to analyze the expression of the following
genes: F4/80, CD11c, CD206, MCP-1, NOS, ARG, TNFα, and TGFβ. Potential reference
genes (18s, HMBS, TBP, B2M, H2AFV, and HPRT) were analyzed for stability using
Qbase+ software (Biogazelle, Belgium) for each tissue analyzed. The optimal number of
reference genes were determined by Qbase+ and the geometric mean of these genes was
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used as the normalization factor for each analysis: TAM (B2M and H2AFV), gonadal
adipose tissue (H2AFV, 18S, HPRT, HMBS, TBP), and subcutaneous adipose tissue
(B2M, TBP, HMBS) [50, 119]. Gene expression quantification was calculated using the
ΔΔCT method and Qbase+ software. Values were normalized to the LFD female group.
Micro Computed Tomography (CT) Quantification of Fat Volume: Following 20 weeks of
diet feeding mice were placed under brief anesthesia (isoflurane inhalation) and positioned
with both legs fully extended on the bed. The torso was scanned at an isotropic voxel size
of 44 mm FOV (70kVp, 114uA) for 18seconds using Quantum GX micro CT Imaging
System (Perkin Elmer). Using, AccuCT micro CT analysis software, all scans were
calibrated to Hounsfield Unites (HU) based on the standard densities of plastic (40) and air
(-1000) plotted against the measured density at the time of scanning. All scans underwent
low pass filter to remove background noise and cropped to a region of interest between L1
and L5 of each mouse. Threshold objects of bone (>500 HU), soft tissue (75-500 HU) and
adipose tissue (<75 HU) were applied to all scans. Subcutaneous and visceral adipose
tissue was differentiated using the abdominal wall as an anatomical landmark (adipose
superficial to the soft tissue layer was marked subcutaneous and all adipose deep marked
as visceral). Volumes of specified objects (bone, soft tissue, visceral fat and subcutaneous
fat) were calculated using AccuCT micro CT analysis software. Volumes of adipose tissue
were then normalized to the soft tissue volume calculated within each scan [146].
Statistical Analysis: Data were analyzed using commercially available statistical software:
Prism 6 (GraphPad Software, La Jolla, CA). A two-way ANOVA followed by a turkey
post-hoc analysis was used to determine differences between diet (HFD vs. LFD) and
hormone status (female intact estrogen+/testosterone-; female OVX estrogen-
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/testosterone-; and male estrogen-/testosterone+). For correlation calculations values were
plotted on an XY plot and a Pearson correlation was performed with a two tailed 95%
confidence interval and significance set to p<0.05. Any statistical test that did not pass the
equal-variance test (Bartlett’s test for equal variances) was log transformed and then reanalyzed. Data are presented as the mean ± SEMs and the level of significance was set at
p<0.05.
4.4 RESULTS
20 weeks of HFD feeding leads to an obese phenotype that is exacerbated in male and OVX
mice
At 9 weeks of age mice received either a sham or ovariectomy surgery to establish
male, female, or OVX groups. Two weeks following surgery, mice were fed a 40% HFD
or a purified LFD for 20 weeks. An obese phenotype was successfully achieved as the
HFD-fed mice gained significantly more body weight, fat mass, and displayed a
significantly greater body fat % (Figure 4.1 A-B) compared to LFD fed mice (p<0.05).
HFD-fed mice also displayed elevated fasting blood glucose, insulin, HOMA-Index, GTT
AUC, and impaired insulin sensitivity (Figures 4.1 D-J), demonstrating a dysfunctional
metabolic phenotype (p<0.05). Further, within a high fat diet, male mice exhibited
increased body fat mass (p=0.01), lean mass (p<0.0001) and HOMA-Index (p<0.0001)
compared to intact female mice, indicating that females exhibit a slight protection against
diet induced obesity. However, this observed protection was not as prevalent in the HFD
OVX group, which exhibited increased body weight and fat mass (p<0.0001) with trending
increased body fat%, GTT, and HOMA-index although these were not significantly
increased compared to HFD females. Further, this OVX group resulted in decreased bone
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mineral density compared to intact females or males, independent of diet, a common
consequence of estrogen depletion as estrogen is important for bone calcium reabsorption
(Figure 4.1 C).
Tumor weight is increased in obese mice and is most severe in HFD OVX group
Following MC38 cell injection, tumors were allowed to grow for 3 weeks before
weights were measured. Consistent with epidemiological evidence, HFD resulted in
increased tumor weight compared to LFD (Figure 4.2 A). This was consistent with
increases in spleen and liver weight of the HFD mice compared to LFD (Figure 4.2 B-C).
As expected, adipose tissue of all depots measured was significantly increased as a result
of 23-week HFD feeding (Figure 4.2 E). Additionally, HFD feeding significantly increased
white blood cells, specifically lymphocytes and neutrophils within whole blood (Figure 4.2
F). Interestingly, the HFD OVX group presented with the largest tumors of any group,
significantly larger compared to female and male groups within the same diet treatment
(Figure 4.2 A p=0.036 and 0.001 respectively). This increase in tumor weight within HFD
OVX was consistent with increased white blood cells, specifically neutrophils (p=0.005)
(Figure 4.2 F). However, contrary to the epidemiological data, HFD feeding in male mice
did not significantly increase tumor weight. Further, the tumor challenge resulted in
reduced gonadal adipose tissue and subsequent total adipose weights measured 3 weeks
following tumor initiation compared to female and OVX mice within the same diet
(p<0.0001) (Figure 4.2 E). Despite the reduced tumor weight and gonadal adipose tissue,
HFD male mice presented with increased white blood cells, specifically lymphocytes and
neutrophils, similar to the HFD OVX mice. The phenotypic differences between female
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and OVX groups were further confirmed by significant decreases in uterus weight of the
OVX groups compared to the female groups (p<0.0001) as shown in figure 4.2 D.
Tumor associated macrophages isolated from female and OVX tumors exhibited different
phenotypes
Due to the unchanged tumor growth observed in the lean compared to obese male
mice, we decided to focus on the interaction solely between female intact and OVX mice
within respective diets. Following tumor excision, TAMs were defined as double positive
F4/80 and CD11b cells from a CD45 positive gate and were collected using FACS (Figure
4.3 A). Although there were differences in tumor weight as seen in Figure 4.2 A, between
HFD OVX and female mice, there were no significant differences in the TAM percentage
within these tumors (Figure 4.3 B). However, upon further investigation of the gene
expression in these isolated TAMs, CD11c, an M1 macrophage marker was significantly
increased in female mice (p=0.05), consistent with a significant decrease in expression of
CD206, an M2-macropahge marker (p=0.02) (Figure 4.3 C-D).

This indicates that

irrespective of tumor size or diet, female mice possess more pro-inflammatory/ anti-tumor
macrophages within the tumor microenvironment compared to OVX mice. However,
because TAMs were isolated from tumors of different sizes it is unclear whether this altered
macrophage phenotype directly impacted tumor growth or is simply a consequence of the
difference in tumor size.
Spleen, total fat and fasting insulin levels are positively correlated with tumor weight of
female and OVX mice.
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In order to further examine potential mechanisms of the increased tumor size within
OVX mice, tumor weight was plotted against spleen, total fat and fasting insulin levels
(Figure 4.4). Consistent with other cancer models, tumor size was strongly correlated with
increased spleen size (R2=0.6017, p<0.0001), confirming that an increased immune
response is present following tumor challenge. Additionally, there was a significant
positive, albeit weak, correlation between total visceral fat (R2=0.294, p=0.0008) compared
to tumor weight as well as fasting plasma insulin levels (R2=0.4151, p<0.0001) compared
to tumor weight suggesting a potential link between fat distribution or insulin sensitivity
and tumor growth.
Differential fat distribution of visceral and subcutaneous fat among female and OVX mice
following 20-week diet feedings
The significant correlation between tumor weight and total fat shown in Figure 4.4
B, led us to initiate a new cohort of female and OVX mice subjected to the same low fat or
high fat diet treatment for 20 weeks. This helped us understand the environment at the time
of MC38 injection as opposed to 3 weeks following tumor growth. As reflected in the
DEXA analysis in the previous study (Figure 4.1B), 20 weeks of HFD feeding resulted in
significantly increased body fat %. Although within the HFD, no difference in body fat %
was observed between OVX and female mice. To better understand distribution of fat
rather than total body fat%, the new cohort of mice were scanned using micro CT which is
considered more accurate and sensitive than DEXA and can distinguish between visceral
and subcutaneous fat [146]. As seen in the representative images in Figure 4.5 A, bone,
soft tissue, visceral fat and subcutaneous fat were able to be distinguished based on
differing densities, and quantified by volume within the region of interest, L1 and L5. The
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micro CT analysis in Figure 4.5 B-C, confirmed, that in addition to increased visceral
adipose tissue, HFD mice had significantly increased subcutaneous adipose tissue
compared to LFD mice (p<0.0001). Further, OVX mice had significantly increased
subcutaneous fat distribution compared to female mice within either LFD or HFD groups
(p=0.04 and p=0.03, respectively). In order to confirm the accuracy of the micro CT
analysis to measure adipose volume, a correlation between visceral adipose tissue weight
taken at sacrifice and visceral adipose volume calculated via micro CT scan revealed a
strong positive correlation (R2= 0.9793 and p<0.0001) (Figure 4.5 D).
Increased macrophage infiltration and associated inflammation in adipose tissue of HFD
OVX mice
As expected, a main effect of diet was achieved through increased F480, MCP1,
CD11c, CD206, NOS, ARG-1, TNF and TGFβ gene expression within HFD parametrial
adipose tissue compared to LFD adipose tissue (p<0.05) (Figure 4.6). Additionally, within
the HFD group, OVX mice presented with greater adipose inflammation with significant
increased F480, MCP1, CD11c, CD206, NOS, ARG-1, TNF and TGFβ compared to
female mice (p<0.01). This severe inflammation presented only in the adipose tissue of
HFD OVX mice, supporting that intact female mice are to a certain extent protected against
obesity induced adipose tissue inflammation. The subcutaneous adipose tissue gene
expression revealed no significant difference in F4/80 macrophage gene expression in
contrast to a significant increase in MCP-1 within HFD compared to LFD (p=0.01).
Among HFD fed mice, OVX mice had significantly increased MCP-1 concentrations
compared to female (p=0.05). Additionally, OVX mice displayed a significant increase in
the pro-inflammatory macrophage marker CD11c compared to female mice within HFD
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(p=0.001). These differences indicate that inflammation is unique within visceral and
subcutaneous adipose tissue depots and that HFD OVX mice have greater adipose tissue
inflammation compared to HFD female mice.

4.5 DISCUSSION
Given the established link between obesity and CRC along with a suggested
interaction of sex specific hormones, we examined sex disparities within colon derived
cancer growth following diet-induced obesity. Using the subcutaneous MC38 tumor
model, we were able to replicate some epidemiological data, as we observed enhanced
tumor growth following diet-induced obesity and insulin resistance. Within female mice
on a high fat diet, some protection against obesity-enhanced tumor growth was observed
compared to ovariectomized mice.

However, male mice failed to coincide with

epidemiological data and did not exhibit increased tumor growth compared to females fed
the same diet. It was revealed in a follow up study, that following 20 weeks of high fat
diet feeding, OVX mice had significantly increased visceral and subcutaneous fat
compared to female mice. These adipose tissue depots within HFD OVX exhibited more
severe macrophage associated inflammation through observed increases in CD11c, M1
macrophage gene expression.

Taken together these data suggest that accelerated

subcutaneous tumor growth within obese OVX mice may be due to the increase in
subcutaneous adiposity combined with increased M1, pro-inflammatory adipose tissue
macrophages.
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The association between obesity and CRC has been suggested in both
epidemiological and in-vivo mouse studies.

Epidemiological evidence has further

uncovered a more significant relationship in men than in women [42-44]. A meta-analysis
of 18 observational studies showed a 20% reduction in colon cancer incidence among
women who had ever used HRT, indicating a specific association between female sex
hormones and CRC [47]. Utilizing in-vivo subcutaneous tumor models, many have
reported that obesity enhances colorectal tumor growth [147-150]. Consistent with our
findings, Yakar et al, revealed similar increases in tumor growth of obese OVX mice
compared to female mice [137]. However, contrary to what we found, this group was able
to show obesity-enhanced tumor growth in males in addition to female and OVX mice
although they did not directly compare all 3 groups within the same experiment [150]. Our
study is the first to include male, female and OVX mice in an obesity-enhanced
subcutaneous tumor model in order to directly examine sex disparities within this cancer
model.
Although there is evidence to support sex differences in obesity enhanced CRC, a
clear mechanism has yet to be elucidated. Macrophage associated inflammation has been
implicated in obesity induced insulin resistance and CRC which may offer an explanation
for the large tumors present in HFD OVX mice. We observed that in addition to large
tumors, HFD OVX mice presented with more pro-inflammatory macrophages within both
the visceral and subcutaneous adipose tissue depots.

M1 macrophage derived

inflammatory cytokines, including NOS and TNF- which were both increased in our HFD
OVX parametrial adipose tissue, can activate the inflammatory pathways NFB and
STAT3 to mediate proliferation, invasion, angiogenesis, survival and metastasis [151,
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152]. This is consistent with our findings that pro-inflammatory adipose tissue
macrophages present at the time of MC38 injection in HFD OVX mice may have resulted
in the increased tumor weight that was observed 3 weeks post injection.
In addition to inflammation, distribution of adiposity may play an important role in
colon carcinogenesis [153]. In the present study, utilizing highly accurate micro CT
analysis, we found increased visceral and subcutaneous adipose tissue within HFD OVX
mice compared to female mice. There is emerging evidence that adipose stromal cells may
be a source of stromal cells in tumor microenvironments. In animal models of obesity,
adipose stromal cells from inflamed visceral adipose tissue can migrate to tumor sites
[154]. These, stromal cells present in the tumor microenvironment can promote
angiogenesis and support tumor progression[18]. This offers evidence that increased
adiposity within HFD OVX mice may have resulted in increased adipose derived stromal
cells in the tumor and these stromal cells promoted tumor growth. However additional
studies are necessary to confirm this hypothesis.
There is some evidence that female sex hormones may offer a protection against
CRC. In vitro findings have shown that estradiol in addition to estrogen receptor  agonist
can inhibit proliferation and migration of MC38 cells [155, 156]. In several in-vivo studies,
exposure of ovariectomized rats to estrogen reduced the rate of colon tumors by 71% [138,
157]. In addition, in the ApcMin/+ mice ovariectomy resulted in an increased number of
polyps, whereas estrogen replacement in these mice reduced the number of polyps to the
baseline levels [158]. Our data is consistent with these findings, as the female mice
presented with smaller tumors compared to ovariectomized mice. Moreover, the tumorassociated macrophages within female tumors had higher expression of CD11c with
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reduced expression of CD206 compared to OVX mice. This shift in the M1/M2 like TAM
ratio suggests a more tumoricidal environment that coincides with the reduced tumor size
of female mice. Taken together our results indicate a potential for sex hormones present
in females to influence tumor growth and TAM phenotype.
In addition to macrophage associated inflammation, adiposity and estrogen
influencing CRC, emerging evidence indicates insulin as a mechanism for cancer
proliferation. Obesity leads to insulin resistance and results in increased circulating insulin.
A proliferative role of insulin has been reported in various cancers including breast cancer,
pancreatic cancer and CRC [159, 160]. Hvid et al, reports that treatment with insulin
accelerates tumor growth, specifically in the MC38 subcutaneous tumor model [161].
Additionally reducing circulating insulin levels may be beneficial in cancer prevention, as
treatment with metformin, a type 2 diabetes drug, is associated with reduced incidence of
breast cancer in women [162]. Consistent with primary literature, we report a positive
correlation between tumor weight and fasting insulin levels in female and OVX mice,
although we did not explore this potential mechanism further in this study.
An unexpected finding that conflicts with the previously stated evidence was that
tumor growth in HFD males was not increased compared to LFD males despite the
significantly high level of fasting insulin. One possible explanation could be that in
addition to fasting insulin levels, macrophage infiltration and pro-inflammatory
macrophages in the adipose tissue of obese male mice were also significantly increased
compared to both the OVX and female mice within the high fat diet (data not shown).
Although chronic low-grade inflammation is often cancer promoting, perhaps severe acute
inflammation induces apoptosis.

It is possible that the chronic mild inflammatory
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environment of the high fat diet OVX mice combined with the high levels of circulating
insulin was conducive to cancer growth while the severe inflammation in the male mice
offset any proliferative effects of the increased circulating insulin. Of course, additional
studies, involving insulin, insulin knockout mice, or insulin antagonists would be required
in order to test this hypothesis.
In conclusion, our study confirms that obesity enhanced CRC was achieved
following 20 weeks of a high fat diet using a subcutaneous MC38 tumor model, thus
validating this model for future studies. We established that diet induced obesity and
associated insulin resistance present differently in male, female and OVX mice.
Additionally, increased accumulation of subcutaneous fat and increased pro-inflammatory
adipose tissue macrophages at the time of tumor challenge, are likely responsible for the
accelerated tumor growth observed in the high fat diet OVX mice. This study provides
insight into potential mechanisms behind female associated protection against obesity
associated CRC.
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4.6 FIGURES & LEGENDS

Figure 4.1 Body composition and metabolic assessment after 20 weeks of dietary treatment
prior to injection of MC38 cells. A) Mouse body weight, B-E) body composition, fat mass,
lean mass, fat%, and bone mineral density, respectively F-G) intraperitoneal (IP) glucose
tolerance test (GTT) and corresponding area under the curve (AUC), H-I) IP insulin
tolerance test (ITT) following a 5-hour fast and corresponding AUC. J) fasting (5 hour)
blood glucose levels, K) fasting (5 hour) plasma insulin levels, L) Homeostatic Model
Assessment Index – Insulin Resistance (HOMA‐IR) calculated as fasting insulin (μU/ml)
x fasting glucose (mmol/l)/22.5. Values are means ± SE; n=12-15 mice per group. Bar
graphs not sharing a common letter are significantly different from one another (p<0.05).
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Figure 4.2 High fat diet feeding increased tumor weight with enhance growth in OVX
group. A) Tumor weight measurements 3 weeks post injection B-D) Organ weights of
spleen, liver, and uterus (females only), respectively. E) Weight of various adipose depots
with total fat as the sum of gonadal, mesentery and kidney weights. F) Complete blood
count of whole blood. Values are means ± SE; n=9-15 mice per group. Bar graphs not
sharing a common letter are significantly different from one another (p<0.05)
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Figure 4.3 Differential tumor associated macrophage phenotype in female and OVX
groups.
A) Representative gating strategy for collection of tumors associated
macrophages, defined as CD45+ F4/80+ CD11b+ cells. B) Percentage of tumor associated
macrophages within tumors at time of sort. C-D) Quantitative RT-PCR assessment of gene
expression in sorted tumor associated macrophages. Ct values relative to average of
multiple internal controls determined using qBASE pro software analysis. Values are
means ± SE; n=3-4 mice per group. Bar graphs not sharing a common letter are
significantly different from one another (p<0.05)
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Figure 4.4 Tumor weight positive correlated with spleen, fat and fasting insulin levels
among female and OVX mice. Correlation between tumor weight and A) spleen weight,
B) total fat weight, C) fasting insulin from plasma. Data analyzed using Pearson
correlation set to 95% confidence two tailed with significance set to <0.5)
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Figure 4.5 Micro CT imagining of mice at 20weeks DIO reveals differential fat
distribution. A) Representative micro CT images of defined objects based on density
thresholds, bone, soft tissue, visceral fat, subcutaneous fat, B-C) Quantification of adipose
volume based on defined objects within micro CT scans. Volumes relative to soft tissue
volumes, D) Pearson Correlation between quantified volume of visceral adipose tissue via
micro CT and visceral adipose tissue weight taken at sacrifice. Values are means ± SE;
n=8-9 mice per group. Bar graphs not sharing a common letter are significantly different
from one another (p<0.05)
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Figure 4.6 Gene expression of macrophage markers and associated inflammation in
parametrial adipose tissue. Relative gene expression of F480, MCP-1, CD11c, NOS, TNF,
CD206, ARG, TGF of mRNA isolated from parametrial adipose tissue. Ct values relative
to average of multiple internal controls determined using qBASE pro software analysis.
Values are means ± SE; n=8-9 mice per group. Bar graphs not sharing a common letter
are significantly different from one another (p<0.05)
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Figure 4.7 Gene expression of macrophage markers and associated inflammation in
subcutaneous adipose tissue. Relative gene expression of F480, MCP-1, CD11c, NOS,
TNF, CD206, ARG, TGF of mRNA isolated from the dorsal-lumbar portion of the inguinal
adipose tissue. Ct values relative to average of multiple internal controls determined using
qBASE pro software analysis. Values are means ± SE; n=8-9 mice per group. Bar graphs
not sharing a common letter are significantly different from one another (p<0.05)
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CHAPTER 5
SUMMARY AND CONCLUSIONS
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Macrophages play a variety of roles during the development of chronic
inflammation and are a driving force behind inflammation induced insulin resistance and
inflammation association CRC. There is further evidence to support that sex disparities
within these inflammatory diseases may be in part associated with the influence of sex
hormones on macrophage behavior. In the present study, I have examined the effect of
eliminating macrophage associated inflammation in either the context of CRC or obesity
as a potential therapeutic treatment for these inflammatory driven diseases. I have also
uncovered a possible mechanism for sex disparities within obesity enhanced CRC
attributed to differential fat distribution and adipose inflammation.
As presented in my first study, reducing macrophages using clodronate
encapsulated liposomes during the late stage of the chemically induced AOM/DSS CRC
model, was effective at a reducing both colon polyp number and size compared to vehicle
treated AOM/DSS mice. Although clodronate was not able to rescue tumor grade, through
histopathological evaluation of dysplasia or disease symptom scores. This reduction in
colon polyp number was attributed to reduced colon macrophages, in particular protumoral TAM cytokines.

Consistently, there was reduced activation of oncogenic

proliferation pathways including p38, ERK and STAT3 observed in the colon of
macrophage depleted mice. Lastly, macrophage depleted mice, presented with a unique
gut microbiota composition rich in beneficial, butyrate producing flora.

This study

concluded that in the late stages of CRC, TAMs predominate, and that decreasing these
macrophages and associated cytokines through CLD-liposomes resulted in a reduced
diseased state with improved outcome.
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Conversely, in the context of the inflammatory driven disease obesity, depletion of
macrophages resulted in a compensatory reaction that exacerbated and worsened the
disease state. This rationale that if macrophage depletion is in fact beneficial in late stage
CRC perhaps, it would offer similar benefits in obesity associated insulin resistance, since
insulin resistance is closely linked to CRC.

However, depletion of adipose tissue

macrophages, following diet induced obesity, was ineffective at rescuing obesity
associated metabolic function. In fact, macrophage depletion exacerbated inflammation
and resulted in neutrophilia observed through increased adipose tissue and circulating
neutrophils. We concluded that in the absence of macrophages during the obese state,
neutrophils infiltrate into the adipose tissue in response to MCP1, exacerbating tissue
specific and systemic inflammation. This compensatory reaction therefore negates any
potential benefit of macrophage depletion in the context of obesity. These results highlight
the importance of macrophage presence within adipose tissue and encourage therapies that
specifically target macrophage associated inflammation without affecting macrophage
number.
Lastly, in Chapter 4, we used mouse models of obesity and CRC, to examine
macrophage associated inflammation on obesity enhanced CRC with respect sex
disparities. It was observed that high fat diet feeding accelerated tumor growth with HFD
OVX exhibiting the largest tumors. We proposed that this increase in tumor growth in the
OVX group is related to increased adiposity and macrophage associated inflammation
within the adipose tissue.

Although, these results did not completely agree with

epidemiological data, they were able to uncover sex differences in adipose tissue
distribution and macrophage associated adipose inflammation. This study provides insight
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into potential mechanisms underlying protection of females against obesity associated
CRC.
Taken together, these data suggest that macrophages differentially impact obesity
and CRC. While clodronate mediated macrophage depletion may not provide a global
treatment for all inflammatory driven diseases, it provided further insight into the diverse
functions of macrophages in the context of obesity and CRC. Additionally, a potential
mechanism for sex-disparities in CRC may involve macrophage associated inflammation.
Due to the prevalence of obesity and CRC worldwide, any evidence that suggests potential
mechanisms for these inflammatory driven diseases are profoundly important. However,
further studies are needed to explore therapies targeting macrophage associated
inflammation in obesity and CRC.
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CHAPTER 6
FUTURE DIRECTIONS
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In these studies, we focused primarily on the progression of CRC or diet-induced
obesity in the absence of macrophages in order to better understand the role of
macrophages in these diseases. Although it was effective at depleting macrophages,
clodronate treatment resulted in significantly decreased food intake of mice. In order to
confirm that the results we observed in chapters 2 and 3 were specifically related to
macrophage depletion and not the clodronate treatment, it would be important to further
test our hypotheses using an alternative method to deplete macrophages. Further, given
the differential importance of macrophage phenotype in obesity and CRC, it would be
interesting to focus our approach by targeting macrophage subsets or tissue specific
macrophages rather than total macrophages.

Although specific M1 or M2 targeted

macrophage depletions are difficult, the utilization of LysM Cre- crossed with a loxP site
targeted to NOS or ARG, the common M1 and M2 expressing macrophage gene,
respectively, could prove effective at phenotype specific targeting within either the obesity
or CRC models previously used.
Our results in Chapter 4 indicate that sex specific differences are observed in an
obesity enhanced tumor model and that macrophage associated inflammation may play a
role. It would be important to follow up this study to include the addition of both an
estrogen and progesterone to further validate our hypothesis that female sex hormones offer
some protection. Additionally, emerging evidence supports the influence of insulin in
tumorigenesis and cancer risk. Targeting insulin, either through addition of insulin, insulin
inhibitors or by transfecting the MC38 cells to become insulin receptor deficient would
offer a more mechanistic approach to examine insulin specific effects on tumorigenesis.
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